Induction of estradiol-2-hydroxylase by isoprenyl compounds. by Wong, Che-cheuk Dobe. & Chinese University of Hong Kong Graduate School. Division of Biochemistry.




WONG Che-cheuk, Dobe 
B. Sc. (Hons) in Biochemistry, HKU 
A'thesis submitted in partial fulfillment of 




The Chinese University ofHong Kong 
I^^^^  
r ( 1 5 JUL 1989ji| 
\%r~~ UNIVERSITY“~~^麗 
V5^ XLIBRARY SYSTEM^^/^ ^^^^ 
i 
Acknowledgements 
I would like to express my upmost gratitude to my supervisors. Professors 
Y.C. Kong and W.P. Fong, for their continuous patient guidance and 
encouragement throughout my M. Phil, studies . 
Many thanks are due to Professors S.S.T. Lee and D.C.C. Wan and 
especially my external examiner, Professor R.K.M. Ko, Department of 
Biochemistry, the University of Science and Technology, for their willingness to 
be members of my thesis committee. Thanks also go to Professor S.S.T. Lee for 
her supply of aryl hydrocarbon receptor knockout mice, which enhance me to 
fmish my project. I am also indebted to Professor D.C.C. Wan for giving 
comments on the manuscript. 
^ 
I would like to thank Ms. E.Y.M. Chan, Ms. S.F. Lee and Mr. H.Y. Fok for 
their helps in the preparation ofthe figures and diagrams in the thesis. 
Finally, I would like to express sincere thanks to the staffs and students in 
the Department of Biochemistry, for their assistance during the past two years; 




Estrogen can be hydroxylated at both 2- and 16a- positions. These two reactions 
are mutually exclusive. 2-Hydroxylated estrogen is relatively inert compared with the 
16a-derivative; hence, one approach in anti-estrogenic therapy is to look for drugs that 
can induce the 2-hydroxylation pathway. In the present stiidy, by using Balb/c and 
C57/B6 mice as the animal models, the induction effect of several isoprenyl compounds 
on estradiol-2-hydroxylase and ethoxyresorufm-0-deethylase activities were studied. 
The compounds examined included 2'- and 3'-methylbutadienyl-indoles and their 
respective acid condensation products, isopropyl indolocarbazole and yuehchukene; 
positional isomers of indole carbinols and carboxyaldehydes, as well as 3-
methylcholanthrene, the prototype inducer of cytochrome P450 1A1. The results 
demonstrated that while all of them were able of inducing cytochrome P450 1A1-
mediated ethoxyresorufin-0-deethylase activity, only the 3’ isomers could induce 
estradiol-2-hydrox3^ 1ase activity. The induction of these two activities did not show any 
correlation, suggesting that cytochrome P450 1A1 was not the same enzyme catalyzing . 
both ethoxyresorufm-0-deethyiation and estradiol-2-hydroxylation. Nevertheless, both 
inductions were mediated by the aryl hydrocarbon receptor, as mice with the aryl 
hydrocarbon receptor knockout failed to show any induction upon treatment. By using 
inhibitor specific for different forms of cytochrome P450s, it was shown that cytochrome 
P450 3A4 maybe one ofthe P450s responsible for the estradiol-2-hydroxylation. On the 
other hand, all compounds failed to induce or suppress aromatase activity. Yuehchukene, 
iii 
like the indole carbinols, was also capable of scavenging free radical. This may also 
contribute to the beneficial effect of yuehchukene. 
• •• >A^>- ••. 




卵巢素是可以於 ( > 2位和 0 > 1 6位進行經化反應’ 
而這兩個反應是因用同一基質而相互排斥的。 2 -經 
化後的卵巢素是失效的，反之 1 6 -經化後的卵巢素 
更具長效。故此抗卵巢素療法的根據便是尋找能 
夠激活 2 -經化反應的藥物，從而增加 2 -羥化卵巢 
素的份量。在這項指導思想下的硏究中運用小白鼠 
( B a M 0和小黑鼠 ( C 5 7颇 )作爲動物模型，硏究了數 
種異戍二焼嘲噪在對 3 - 1 7二經卵巢素 - 2 -經化酶 
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\但只有 3’位上的同分異構物能钩激活 3 - 1 7二經卵 


















A B T S : 2-2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
E D T A : Ethylenediaminetetraacetic acid 
E2-2-OHase : Estradiol-2-hydroxylase 
E R O D : Ethoxyresorufin-0-deethylase 
F S H : Follicle stimulating hormone 
G n R H : Gonadotrophin releasing hormone 
Hepes : N-[2-Hydroxyethyl]piperazine-N'-[2-ethenesulfonic acid] 
I-2-C : Indole-2-carbinol 
I-2-CA : Indole-2-carboxyaldehyde 
I-3-C : Indole-3-carbinol 
I-3-CA : Indole-3-carboxyaldehyde 
EPP-ICZ : Isopropyl indolo-carbazole 
L H : Luteinizing hormone 
2'-MBDI : 2'-methylbutadienyl-indole 
3 '-MBDI : 3'-methylbutadienyl-indole 
3-MC : 3-methylcholanthrene 
M R O D : Methoxyresorufin-0-deethylase 
N A D P : P-Nicotinamide adenine dinucleotide phosphate 
N A D P H : P-Nicotinamide adenine dinucleotide phosphate, 
reduced form 
P O P O P : Dimethyl-1,4-bis-(2-(5-phenyloxazol))-benzene 
PPO ： 2,5-diphenyloxazole 
S.D. : ‘ Standard deviation 
T C A : Trichloroacetic acid 
T C D D : 2,3;7,8-tetrachlorodienzo-p-dioxin 
Tris : Tris, (hydroxymethyl)aminomethane 
Y C K : Yuehchukene 
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1.1 Stages of Cancer Development 
How cancer develops is no longer a mystery. During the past two decades, 
much progress has been made iii fmding how cancer is formed. Cancer 
development begins when some cells within a normal population sustain a genetic 
mutation that increases its propensity to proliferate when it should normally rest. 
The altered cells and their descendants continue to look normal, but they 
reproduce too much and reach a condition known as hyperplasia. The ceUs further 
lose control on cell growth. In addition to excess proliferation, the offsprings of 
these cells appear abnormal in shape and orientation, the tissue is now said to 
exhibit dysplasia. If the tumour has not yet broken through any boundaries 
between tissue, it is known as in situ cancer. This tumour may remain contained 
indefinitely; however some cells may acquire additional mutation. As a result, 
_ 
these cancer cells become “deaf，to usual control; instead, they only follow their 
own internal signal for proliferation. Furthermore, genetic changes allow the 
tumour to invade underlying tissue and shed cells into blood or lymph. Then the 
mass is considered to have become malignant and the renegade cells are likely to 
establish a new tumour as the cells adhere on the other surface. Adhesion of cells 
to the new surface allows them to survive, proliferate and disrupt other vital 
organs. This is normally how carcinoma develops. 
^v 
1.2 Comparison of Breast Cancer in Hong Kong & the United 
States 
1.2.1 Statistics of Breast Cancer in the United States 
Among different kinds of cancer (except basal cells and squamous ceU skin 
cancers which are very common but rarely fatal), breast cancer affects most 
women in the United States, hi 1996，a survey showed that 185,700 new cases 
were being diagnosed and 44,560 deaths were expected (Table 1.1). Breast cancer 
ranked third in causing death, after lung and colorectal cancer. However, the 
incidence of breast cancer increases continuously in the past three decades. 
1.2.2 Statistics of Breast Cancer in Hong Kong 
In Hong Kong, the most recent annual report (1995/96) released by the 
Department of Health in 1997 found a similar increasing trend of breast cancer as 
4f 
that observed in the United States. The report revealed 320 deaths caused by 
breast cancer in 1995, which ranked third in the causes of death from cancer, hi 
the study of the crude death rate, breast cancer also occupies a high position 
(Figure 1.1). Moreover, the annual report suggested that more and more patients 
were suffered from breast cancer, as 1,200 new cases were notified to the cancer 
registry in 1992 (Figure 1.2). The trend is very close to that in the United States 
and many factors may attribute to such circumstance. Diet is one of the generally 
^v 
Table 1.1: Top Ten Cancers Found in the United States (1995) 
Type of Cancer New Cases Diagnosed Deaths Expected 
Prostate Cancer 317,000 41,400 
Breast Cancer 185,700 44,560 
Lung Cancer 177,000 158,700 
Colorectal Cancer 133,500 54,900 
Bladder Cancer 52,900 11,700 
Non-Hodgkin's Lymphoma 52,700 23,300 
Uterine Cancer 49,700 10,900 
Melanoma of Skin 38,300 7,300 
Kidney Cancer 30,600 12,000 
Leukemia 27,600 21,000 
(Extracted from “Twelve Major Cancers", 
Sci. Am.，Sept., 1996) 
一 
^v 
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accepted factors, as Hong Kong people have gradually switched to a westem diet. 
For example, the Hong Kong people prefer fast food with high fat content. 
1.3 Factors for Breast Cancer 
1.3.1 Genetic Factor 
Many factors were believed to be related to the occurrence of breast cancer. 
On genetic basis, B R C A 1 and B R C A 2 genes were involved. Mierited mutation 
in either of these 2 genes account for the buUc of familial breast cancer, 
encompassing as many as 5-10 percent of all breast cancer in the United States and 
also a substantial proportion of familial ovarian cancer (Table 1.2). B R C A 1 and 
B R C A 2 were situated on the long arm region of chromosome 17q and 13 
respectively (Comelisse et al., 1996, Casey et al., 1993). Ln terms of B R C A 1，it 
has been shown to account for inherited predisposition to carrier in ahnost all 
families and the c m e r will have a life time risk of either breast cancer or ovarian 
cancer close to 100 percent (Ford et al., 1993). The B R C A 1 expression is not 
directly responsive to estrogen (Marks et al., 1997). B R C A 2 is also suggested to 
play a major role in familial breast cancer. Although the tests for detecting 
inherited mutation in the B R C A 1 and B R C A 2 genes are available, doctors have 
not reached a consensus on their use. 
^v 
About 15% of women who are carriers of mutated B R C A 1 apparently do 
not develop breast cancer (Miki et al, 1994; Hall et al., 1990). hi these cases, 
beneficial exogenous factors may play a positive role by promoting enzymatic 
detoxification of potential carcinogens, D N A repair, antioxidant formation, or by 
otherwise enhancing the ability of the cell to override signals that would produce 
uncontrolled growth. Recently several researchers reported that the average age of 
onset of the disease has fallen in carriers of B R C A 1 as well (Miki et al, 1994; 
Hall et al., 1990). 
Table 1.2: Breast Cancer Risk from Mutation ofBRCA 1 and B R C A 2 
Lifetime Risk from all Causes 1 in 8 to 1 in 10 
Fraction of Cases Caused by Lnherited Susceptibility 5-10% 
Estimated incidence of inherited B R C A 1 mutation 1 in 200 women 
Estimated incidence of inherited B R C A 2 mutation 1 in 200 women 
t0   
(extracted from "Breast Cancer Gene 
Offers Surprise", Science 265,1994) 
1.3.2 Hormonal Factor 
Besides genetic factor, hormonal factor also plays an important role in 
breast cancer. This fact was first recognized empirically by Beatson in 1896 when 
he found that patients with advanced breast cancer can benefit from oophorectomy 
^v 
(surgical excision of an ovary) (Beatson, 1896). The severity and frequent 
occurrence of the disease have focused major research efforts to develop curative 
procedures. One aspect in breast cancer research, endocrine therapy, has had an 
intriguing evolution since the past century. After the practice of Beatson, 
interruption of estrogen interaction with breast epithelium becomes a common 
approach in breast cancer therapy. 
Estrogen is essential in promoting the development of secondary sexual 
characteristics in puberty. It plays an important role in the menstrual cycle. At 
the end of menstruation, the thickness of endometrium rapidly increases under the 
influence of estrogen. Moreover, estrogen is known to preserve or improve some 
of the brain's highest function; stimulate cell growth, improve memory and 
Alzheimer's disease (Tang et al., 1996). Estrogen also acts as a stimulatory 
hormone and increases the frequency of mitotic activity in the target organ, such as 
^ 
the breast and ovary. As a rare consequence of this estrogen-induced proliferation, 
malignant phenotypes develop due to errors in the mechanism of cell division. 
Therefore, breast cancer risk is determined primarily by the total exposure of 
breast tissue to bioavailable estrogen and the associated cumulative mitotic 
activity. Those women exposed to a larger "estrogen window", for example those 
with late occurrence of menopause (after the age of 50), early onset of 
menstruation (before the age of 12) (Table 1.3), or delayed childbearing (after the 
^v 
age of 30), will have a higher risk ofhaving breast cancer (Henderson et al., 1988). 
It is fornid that post-menopausal breast cancer patients had significantly higher 
level of free estrogen than control (Moore et al., 1982). 
It was clearly demonstrated by the above facts that lowering the 
endogenous estrogen level in target tissue would lower the risk of having breast 
cancer, especially in pre-menopausal women, bi fact, this creates a basis for the 
endocrine or hormonal therapy on breast cancer management. This actually 
provides the basis for the action of anti-estrogen like tamoxifen, which was 
originally synthesized for anti-fertility purpose. The mechanism of tamoxifen's 
action will be discussed in Section 1.4.1. 
Table 1.3: Age at menarche and onset of regular cycles and relative risk (RR) ofbreast 
cancer 
Years from menarche to regular cycle 
Age at menarche ‘ 0 M 5+ 
younger than 12 Cases 56 27 18 
Control 51 39 38 
RR 3.7 2.3 1.6 
olderthan 13 Cases 34 17 11 
Control 70 35 37 
^ l_6 \_6 1.0 
(Henderson et al.,1988) 
1.3.3 Genetic Bias 
^v 
Patients with a family history of breast cancer are generally younger and 
have a higher frequency of bilaterality to have such disease (Anderson, 1974). 
The high risk pedigree was those in which mothers of patients also had breast 
cancer, and the sisters of patients had 30-35 % lifetime probability of developing 
the disease (Anderson, 1976). Lower risk families were those in which mothers 
were unaffected but the patient had an unaffected second degree relative or an 
unaffected sister. The lifetime probability of the patients, as compared to their 
remaining sisters in the families was 11 % (Anderson, 1976). 
By comparing the familial and unselected patient, it was discovered that the 
unselected patients had an average bilaterality rate of 3 % (Anderson, 1977). It 
differs significantly from the rate in familial patients and is not unlike the rates 
observed in general series ofbreast cancer patients. Within each group ofpatients, 
the bilaterality rate were clearly higher when the first diagnosis occurred before 49 
^ 
years of age than after this age (Figure 1.3). 
1.3.4 Influence of Diet 
The involvement of dietary fat as a risk factor remains controversial. 
However more and more evidence suggests that consumption of high fat diet was 
related to the development of breast cancer. Besides, researchers have known for 
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laboratory animals. They have also observed that the rates of breast cancer in 
different countries correlate neatly with the amount of fat in a nation's diet. The 
statistics showed that in countries like the United States, Great Britain, the 
Netherlands and other nations which consume high fat diet, there is a higher 
incidence of breast cancer. Meanwhile, in countries such as Japan, Singapore and 
Romania, where the diet is relatively lean, the incidence of breast cancer is only 
one sixth to one half of that in the United States (Figure 1.4). It has been 
hypothesized that high fat intake may act indirectly via the hypothalamus-pituitary 
axis, specifically by raising the concentration of circulating sex hormone, such as 
estrogen (Wynder et al., 1986), which in tum increase the risk of having breast 
cancer. Moreover, the study of estrogen metabolism and excretion in Oriental and 
Caucasian women revealed that the main risk factor for the Caucasian women, 
particularly the Finnish women, whose estrogen level is high, is due to the high fat 
diet and low fecal excretion (Adlercreutz et al., 1994). Besides，intake of 
^ 
vegetable appears to decrease pre-menopausal breast cancer risk and this may be 
related to the presence of P-carotein, lutein and zeaxanthin in vegetable 
(Freudenheim et al., 1996). On the other hand, pooled analyses of case-control 
studies from eight countries with approximately 4,400 cases of breast cancer show 
a 25% increase in breast cancer risk with 100g/ day increase in fat intake. It is 
noteworthy that 100g offat represent 3.8MJ or approximately 40% oftotal energy 
requirement of a normal woman (Howe et al., 1990). 、 
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Obesity is defined as the condition with a body mass index greater than 30 
^ __ 
kg/m . It is common in Europe (Seidell, 1995). Obesity is associated with an 
increased incidence of reproductive dysfunction and estrogen-linked disease 
(Fishman et al., 1975; Schneider et al., 1983). Obesity is affiliated with significant 
decrease in the amount of estrogen with lower estrogenicity and in tum increase 
the risk of breast cancer. Furthermore, adipose tissue is particularly rich in the 
enzyme aromatase. Aromatase catalyzes the conversion of androsteinedione to 
estrone which can be further converted to estradiol. This implies that obese people 
will have more endogenous estrogen than a lean one and subsequently have a 
higher risk ofhaving breast cancer. 
1.3.6 Xenoestrpgen 
Some xenoestrogens, for example anti-androgens and the major metabolite 
of dichloro-diphenyl-trichloroethane (DDT), affect the production and metabolism 
of estradiol and the cumulative changes in the amount of bioavailable estradiol can 
affect the activity of estrogen receptor. Some xenohoraiones and their metabolic 
byproducts can produce free radicals or can otherwise indirectly modify D N A 
structure or fimction. 
^v 
Like estrogen itself, xenoestrogen is a synthetic chemical that can directly 
bind the estrogen receptor. Such compounds differ in their ability to activate the 
receptor. Some persistent synthetic xenoestrogens derived from plastic and 
pesticides can increase the potential for aberrant cell growth. Craig Dees and 
colleagues from the Oak Ridge National Laboratory have recently reported that 
both dichIoro-diphenyl-ethane (DDE), the principal metabolite of DDT, and Red 
Dye No.3, a food colorant, markedly increase proliferation in human breast cancer 
cells that are estrogen receptor-positive (Davis et al., 1997a). Ana Soto of Tufts 
University has shown that combinations of commonly encountered environmental 
materials can have more than multiplicative effects on breast cancer cell growth in 
these same cell cultures. Other xenoestrogens in some spices，herbs and foods also 
bind to the estrogen receptor and cause it to become less active, effectively 
blocking or at least dampening cell proliferation (Davis et al., 1997a). 
-
1.4 Hormonal Therapy in Breast Cancer 
After the discovery of Beatson in 1896 that ovariectomy would cause 
tumour regression in pre-menopausal patients, it was further illustrated that 
removal of the source of estrogen can reduce the incidence of breast cancer. 
Chemicals that reduce endogenous estrogen become popular candidates for the 
treatment or management of breast cancer. Normally, chemotherapy always 
^v 
accompanies surgical intervention, which provides the most effective way for 
curing breast cancer. 
hi the medical treatment of breast cancer, determination of hormone 
receptor is important. Though most of the cases of breast cancer are characterized 
as hormone-dependent breast cancer, there remains a certain number of patients 
having hormone-independent breast cancer, i.e. no hormone receptor is being 
involved and they do not respond to chemotherapy. Radiotherapy, combined with 
surgical treatment, should be introduced to these patients. Lti fact, an ideal targeted 
antiestrogen to be developed as a new hormone replacement therapy for 
postmenopausal women should i) lower cholesterol; ii) maintain bone density; iii) 
maintain estrogenic properties in CNS, but anti-estrogenic in breast; iv) not form 
D N A adduct; and v) cause no uterine stimulation (Gradishar and Jordon, 1997). 
一 
1.4.1 Antiestrogen 
The mechanism of antiestrogen is that the steroid hormone antagonists 
compete with estrogen for the estrogen receptor. However, the antiestrogen failed 
to start a normal physiological response. As a result, the action arises from 
estrogen would be terminated. The main application of antiestrogen is on birth 
control and the treatment of hormone-dependent cancer. Among the different anti-
estrogens, the most widely acceptable drug is tamoxifen. Tamoxifen is a triphenyl 
^v 
ethylene derivative. It will undergo biotransformation at multiple sites and fmally 
generates a number of metabolites (Figure 1.5) that contribute to its anti-estrogenic 
effect. 
After the conversion to 4-hydroxy-tamoxifen, the compound is thought to 
inhibit estrogen-induced cell growth predominantly by competitive blockage of 
estrogen receptor. When it binds to the receptor, the compound induces receptor 
dimerization, activation and D N A binding, but it fails to induce gene transcription. 
Also, the metabolites of tamoxifen can promote the promoter receptor degradation 
and estrogen withdrawal (Osbome et al., 1996). On the other hand, tamoxifen is 
claimed to exhibit estrogenic properties (Osbome et al., 1996). This has particular 
significance because estrogen can function in preserving bone mineral, so as to 
prevent osteoporosis and Alzheimer's disease (Horowitz, 1993). Moreover, it can 
maintain a lower circulating low density lipoprotein level, that may result in a 
^ 
lower incidence of myocardial infarction (Bilimoria et al., 1996). 
Tamoxifen is claimed to be an effective drug for curing breast cancer. 
However, there are many possibilities that they will eventually build up drug 
resistance (Tonetti and Jordon, 1995). Tamoxifen produces liver cancer in rats at 
high dose (Jordon, 1995). It may also result in second maligency. Specifically, 
tamoxifen is associated with an increase in endometrial cancer (Assikis et aI., 
^v 
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Tamoxifen: R i = H R2 = N-(CH3)2, 
4-Hydroxy tamoxifen: Ri = OH R2 = N-(CH3)2, 
N-Desmethyl tamoxifen : Ri= H R2 = NH-CH3, 
Tamoxifen N-oxide : Ri = H R2 = ON-(CH3)2， 
Figure 1.5 Chemical structure of tamoxifen and its major metabolites 
^v 
1996). Recently a number of novel anti-estrogens were synthesized and were 
under clinical trial (Gradishar & Jordon, 1997). Preliminary results suggested that 
tamoxifen may be clinically effective in preventing the development of breast 
cancer, particularly in patients who have a high risk of developing second primary 
tumour after surgical removal of the initial tumour. The results of the clinical trial 
are expected in 1999 and an immense amount of data on tamoxifen, in terms of its 
other benefits (e.g. lowering of serum cholesterol and maintenance of bone mass) 
and its undesirable properties (formation of blood clots and uterine 
carcinogenicity) are being collected (Hong and Spom, 1997). 
1.4.2 Progestin Antagonist 
Administration of progestin antagonist is another treatment for breast 
cancer patients. Recently, a synthetic steroid antagonist, R U 486 was found to 
inhibit' the growth of the breast cancer cell, T-47 D (Musgrove and Sutherland, 
1993). R U 486 acts as an antagonist in the regulation of proliferation, i.e. the 
addition of R U 486 can prevent the growth of breast cancer cells. Anti-estrogen 
resistant breast cancer cells can remain anti-progestin responsive and vice versa 
(Horwitz and Freidenberg, 1985). Furthermore, combination of antiestrogen, 
tamoxifen and anti-progestin are more effective than using either agent alone 
(Bardon et al., 1987). These data suggested that the mechanisms by which these 
compounds inhibit cell growth are distinct. 
^v 
The mechanism of anti-progestin is unknown but recent results suggested 
that anti-progestin RU486, like anti-estrogen, acts in early-to-mid G1 phase to 
inhibit transit of T-47 D cells into S phase. The difference between the kinetics of 
the effects of R U 486 cell cycle phase distribution led to the conclusion that 
different mechanisms residt in progestin-mediated and R U 486-mediated growth 
inhibition (Musgrove and Sutherland, 1993). Moreover, it also suggested that R U 
486 is a potent antagonist of progesterone and glucocorticoid (Musgrove and 
Sutherland, 1993). The result revealed that the progesterone-RU 486 complex 
bound to target D N A fails to interact efficiently with transcriptional machinery 
because the receptor is in the wrong conformation, and does not permit efficient 
communication, for example protein-protein interaction (Beck et al., 1993). 
1.4.3 Aromatase Inhibitor 
Aromatase inhibition represents one of the main endocrine treatment 
options in post-menopausal metastatic breast cancer. Aromatase inhibitor is a 
steroidal compound with structure similar to androsteinedione. The fimction of 
aromatase is to catalyze the conversion of the androsteinedione and testosterone to 
estrone and in tum to estradiol. Thus, inhibition of aromatase activity will be 
beneficial to breast cancer patients, as a result of the decrease in the amount of 
endogenous estrogen. 
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In post-menopausal women, peripheral aromatization of adrenal androgens 
in the liver, skeletal muscle and adipose tissue, including the fatty tissue in the 
breast, produces circulating estrogen. The synthesis at peripheral sites is mediated 
by the cytochrome P450 enzyme aromatase. The primary action of the aromatase 
inhibitor is to block the activity of aromatase which catalyzes the synthesis of 
estradiol from the androsteinedione released from the adrenal cortex. 
Aminoglutethimide, a glutethimide derivative, was the first generation of 
aromatase inhibitor. It is originally used as an anti-convulsant (Hannaford, 1997). 
The drug can decrease the estradiol level but maintain the androgen level, hi the 
early 1980, aminoglutethimide was not approved for dosing because its harm 
outweighed its benefits. However recently, a number of progress has been made 
and a number of drugs are synthesized. Formestranel, a steroidal aromatase 
inhibitor, is used in many countries, although it is not yet approved in the United 
States, as it cannot be taken in oral form (Brodie, 1994). Anastrozole is a highly 
potent and selective non-steroidal aromatase inhibitor. The Food and Drug 
Administration, U S A approved this medication in 1995 for treatment of post-
menopausal women as a second line agent, when anti-estrogen therapy failed 
(Baldinger & DeFusco，1996) (Figure 1.6). Unlike tamoxifen, these agents have 
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tamoxifen. On the other hand, the lack of estrogen activity may lead to 
cardiovascular disease and osteoporosis. 
1.4.4 Gonadotropin Releasing Hormone (GnRH) Analogue 
hi women, the ovaries produce estrogen and progesterone. This is 
stimulated by gonadotropic hormones like luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) in the anterior pituitary, bi tum, the anterior pituitary 
is stimulated to release these hormones by GnRH. GnRH is produced by the 
hypothalamus and travels to the pituitary through a specialized portal vascular 
system. The mechanism underlying these inter-relationships is often referred to as 
a negative feedback loop, because high levels of circulating androgen and estrogen 
act on the hypothalamic-pituitaiy unit to reduce the output of GnRH, LH and FSH 
(Gamer, 1994) (Figure 1.7). 
^ 
The physiological effect of GnRH agonist depends on whether it is 
administered intermittently or continuously. For example, when administered in a 
pulsatile fashion similar to human GnRH secretion, GnRH agonist stimulates the 
pituitary, causing release of FSH and LH (Filicori and Flamigini, 1988) (Figure 
1.8). However, when GnRH was administered continuously or in a very large 
dose, GnRH agonist will imtially stimulate the release of FSH and LH and then 
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inhibit the release of these gonadotropins (Filicori and Flamigini, 1988). The 
inhibition is fully reversible upon discontinuation of the drug. 
Normally, both native GnRH and GnRH agonists bind to cellular receptors 
located on the surface of the anterior pituitary. These hormone receptor 
complexes are subjected to metabolic breakdown by the action of peptidase, 
thereby freeing the receptors so that additional GnRH molecules can bind to them. 
However, as GnRH agonists are more resistant to breakdown by peptidase than the 
native one, the number of receptor available for binding to GnRH is reduced. 
Continued administration of GnRH agonists fails to stimulate the production of LH 
• and FSH, and the levels of androgen and estrogen fail (Gamer, 1994). 
Clinical studies have shown that within 4 weeks of initiation of continuous 
therapy, blood levels of sex hormones, e.g. testosterone, estrogen etc. fall to levels 
^ 
seen after oophorecomy or castration (Gamer, 1994). Thus, GnRH agonists are 
potentially effective in treating disorders that are aggravated by estrogen. 
1.5 Metabolism of Estrogen 
The primary target of the drugs discussed in Section 1.4 is to reduce 
endogenous estrogen either directly or indirectly. The major route of estrogen 
metabolism involves the oxidation of estradiol, which leads to the formation of 
^v 
estrone. It is then splitted into two major hydroxylation pathways, 2- and 16a-
hydroxylation in liver. These two pathways are mutually exclusively (Fishman et 
al., 1980). It is of particular significance to control the 2- and 16a-hydroxylation 
pathways because the metabolites in these two pathways exhibit dissimilar 
biological properties. Pathway is shown in Figure 1.9. The metabolite of 2-
hydroxylation are often regarded as "good estrogen" because it will form a short-
lived adduct after binding to the estrogen receptor, and is easily excreted and 
removed. Thus the estrogenicity will be kept in minimal (Bradlow et al., 1996). 
Lti a critical study by Ruiz-Larrea et al. (1994), it was found that 2-hydroxyestrone 
is a potent antioxidant in protecting against iron-induced lipid-peroxidation of rat 
liver microsome, contrary to the hypothesis that catechol estrogens will promote 
oxidation damage and lead to breast cancer. As a result, it can reduce the D N A 
damage and in tum decrease the chance of transcriptional errors. On the other 
hand, 16a-hydroxyestrone is specifically and significantly elevated in women with _ 
clinically identifiable breast cancer 0s[ebert, 1993). This is because the 16a 
hydroxylated estradiol exhibits a persistent, covalent binding to the nuclear 
estrogen receptor. Moreover, the C16a-hydroxylation leads to the formation of 
the electrophilic metabolite, 16a-hydroxyestrone. Treatment of cells with 16a-
hydroxyestrone has been shown to cause D N A damage (Telang et al., 1992). 
Therefore, it will cause mutation and oncogene activation (i.e. tumour initiation) 
and so lead to an increase in cell division errors. Thus, 16a-hydroxyestrone may 
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function as a potent estrogen agonist (Swaneck and Fishman, 1988; Yu and 
Fishman, 1985). More recently, elevated 16a-hydroxyestrone level has been 
demonstrated in breast tissue surrounding a tumour (Bradlow et al., 1996). The 
catecholestrogen is mainly inactivated by 0-methylation catalyzed by catechol-0-
methyltransferases. 
Besides estrogenicity, free radicals are also suspected to be a factor for 
carcinogenesis. Steroids have been shown to induce free radical-mediated damage 
to cellular macromolecule both in vitro and in vivo. This enhanced carcinogenic 
activity is often due to the generation of free radicals that react with 
macromolecules (Miller, 1970). A study by Wyllie and Liehr (1997) showed that 
the redox cycling of estrogen metabolite release ferrous (H) ions from ferritin, 
which in tum generates hydroxyl free radicals by a Fenton reaction. Many 
carcinogens react directly with DNA, R N A and protein, and it is known that the 
reaction products or derivatives can possess great carcinogenic activity. For 
example, metabolism of oxygen involving a chain of one electron reduction and 
the formation of DNA-reactive free radicals plays a pivotal role in causing 
extensive structural and functional damage to DNA. One electron oxidation ofthe 
catechol estrogen, 4-hydroxyestradiol leads to the formation of semi-quinone, a 
reactive species. Semiquinone can be tother oxidized to quinone. Alternatively, 
semiquinones can react to give superoxide ions, which in tum yield the reactive 
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hydroxyl ion moiety. Free radicals induce damage to the phosphodiester bonds 
and alter the D N A nucleotide base sequence, thereby impairing normal 
transcriptional processes (Liehr et al., 1995; Weisz et al., 1992). It has been 
suggested that the relevance of oxidative damage in breast cancer is predominantly 
due to hydrogen peroxide generation (Davis et al., 1997b). Hydrogen peroxide 
can cross the nuclear membrane where it is converted by the iron- or copper-
catalyzed Fenton reaction to generate the free radicals hydroxyl ions. Some 
xenoestrogens and estrogen metabolites promote the production of free radicals by 
redox cycling of hydrogen peroxide mediated by cytochrome P450 oxidase and 
reductase, leading to the production of DNA-damaging reactive oxygen species 
• (Davis et al., 1997b). 
Consequently, modulation of estradiol by channeling into two different 
estradiol hydroxylation pathways will bring benefit to the women, especially the 
postmenopausal women. Currently, considerable attention is drawn on the dietary 
modulator of carcinogenesis as it is well known that dietary factors influence the 
process of carcinogenesis. Several natural products in fruits and vegetables have 
been reported to possess antimutagenic and anticarcinogenic properties. 
1.6 Substances with Chemopreventive Properties towards 
Breast Gaecer 
^v 
Isoflavonoids are plant phenolic compounds. They have a 1,2-
diphenylpropane skeleton, and they are structurally and biologically closely related 
to the flavonoids which are derivatives of 1,3 -diphenylpropane. Moreover，they 
have a limited taxonomic distribution and are largely confmed to the legume 
(Leguminous family). Isoflavonoids are particularly rich in certain legumes, for 
instance, soya, lentils, chick peas etc. These are traditional diets for the Asians 
and Africans. The isoflavonoids are weak estrogens, and possess certain degree of 
estrogenicity, e.g. they can cause hormone dependent cancer growth in some 
situation (Herman et al., 1995; Lee et aI., 1991). Besides such properties, recent 
findings showed that the flavones are capable of acting on the enzymes involved in 
estrogen synthesis and metabolism, for example, they inhibit estrogen specific type 
I 17p-hydrosteroid dehydrogenase (Penning, 1996). These fimctions have been 
attributed to the structure resemblance of isoflavones and estrogens. IsofIavones, 
such as daidzen and genistein, were shown to inhibit enzymes involved in the 
synthesis of estrogens and androstenediol in the breast by modulating activities of 
enzymes involved in sulfoconjugation and sulfohydrolysis of steroids (Wong and 
Keung, 1997). 
Genistein is a flavonoid that is structurally similar to estradiol and binds 
weakly to estrogen receptor. Although genistein has only about one-thousandth 
the estrogen activity, its circulating concentration in individuals consuming a 
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moderate amount of soyfood is nearly one thousand fold higher than the peak level 
of endogenous estradiol in premenopausal women fHerman et al., 1995). 
Moreover, genistein has been reported to act as both an estrogen agonist as well as 
an antiestrogen by inhibiting estradiol-activated cell growth. All these data 
suggest that Asian women only have about one half the circulating levels of 
estradiol and estrone of Caucasian women. The Asian women also have fewer 
health problems associated with estrogen deficiency, despite the fact that they 
reach menopause earlier (Willett, 1994). This may be related to the difference in 
the dietary habit. 
The cruciferous vegetables (e.g., cabbage, brussels sprouts, broccoli, 
cauliflower etc.) contain indole derivatives, dithiolthiones and isothiocyanates. All 
these compounds have been shown to be anticarcinogenic in several rodent 
carcinogenesis models (Wattenberg, 1978; Stoewsand et al., 1988). Hidole-S-
^ 
carbinol (I3C), one of the indole derivatives, inhibits carcinogen-induced neoplasm 
of forestomach and mammary gland (Wattenberg and Loub, 1978). Human 
volunteers fed with I-3-C is found to have a high amount of 2-hydroxyestrone and 
a lower incidence ofbreast cancer (Michnovicz and Bradlow, 1990; Larsen-Su and 
William, 1996). This indicates that I-3-C strongly influences estradiol metabolism 
by channeling the estradiol to form 2-hydroxyestrone in humans and therefore 
provide a new chemopreventive approach to estrogen-dependent disease. The 
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active component for such induction is the acid condensation product 
indolo[3,2(b)]carbazole (ICZ) (Liu et al., 1994). Besides induction ofestradiol-2-
hydroxylation, I-3-C also induces the cytochrome P450 1A1 dependent mono-
oxygenase (Jellinck et al., 1993). 
The protective effect of I-3-C against chemical carcinogenesis has been 
largely attributed to its ability to induce enzymes that facilitate the metabolism and 
elimination of chemical carcinogens. Recently, I-3-C treatment was demonstrated 
to elevate the 2-hydroxylation of estradiol QVIichnovicz and Bradlow, 1990)，which 
could be protective against estrogen-responsive cancers by increasing the levels of 
the anti-estrogenic catechol estrogens such as 2-hydroxyestrone QVIartucci and 
Fishman, 1979; Schneider et al，1984). The induction of CYP lA subfamily 
members (Vang et al, 1980)，which also accompany with high estradiol-2-
hydroxylase activity (Dannan et al.，1986), is thought to be responsible for the 
• 
effects of I-3-C on estradiol metabolism (Michnovicz and Bradlow, 1990). 
Although these two activities are induced by I-3-C, there may not be a direct 
linkage between them. Recent studies with rainbow trout have demonstrated that 
I-3-C exhibits anti-carcinogenic activity in this species but does not induce CYP 
lA dependent ethoxyresourfm-0-deethylase fNixon et al., 1984). Therefore, the 
lack of induction of CYP lA activity by I-3-C in rainbow trout raises questions 
regarding the contribution of CYP lA to the anticarcinogenic activity of this 
^v 
compound. CYP lA is one of several hepatic P450 enzymes that exhibit steroid 
hydroxylase activity. 
1.7 Aryl Hydrocarbon Receptor 
Aryl hydrocarbon receptor mediates many carcinogenic and teratogenic 
effects of environmentally toxic chemicals such as dioxin. It is also a ligand-
activated transcription factor that is distinct from members of the steroid receptor 
superfamily. It is a member of the basic helix-loop-helix superfamily of D N A 
binding proteins and is activated by dimerization with the aryl hydrocarbon 
receptor nuclear translocator. A functional aryl hydrocarbon receptor is required 
in laboratory animals to mediate the harmful effects of toxic environmental 
chemicals such as dioxin, benzo[a]pyrene in cigarette smoking, and the products of 
other combustion processes, polychlorinated biphenyls and polybrominated 
biphenyls (McConkey et al., 1988). The aryl hydrocarbon receptor is 
constitutively expressed in many mammalian tissues, with the highest amount of 
m R N A in liver, kidney, lung, heart, thymus and placenta (Li et al., 1994). 
As a result, aryl hydrocarbon receptor knockout mice should prove useful 
for studies of carcinogenesis and chemical risk assessment with regard to various 
important, highly toxic environmental pollutants. The effects of these chemicals 
on the liver and the immune system without the mediation of aryl hydrocarbon 
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receptor will help to clarify the genotoxic and non-genotoxic pathways for tumour 
initiation, promotion and progression as well as for mutagenesis and toxicity. Li 
addition, this mouse line will help delineate the role of the aryl hydrocarbon 
receptor in normal development of the liver and the immune system. 
1.8 Cytochrome P450s 
Cytochrome 450 enzymes often catalyze the initial step of detoxification 
pathways. The enzymes are notable for their broad and overlapping substrate 
specificity. Under some circumstances, the enzymes will activate their substrates 
to carcinogenic, mutagenic and cytotoxic products (Jellinck et al.，1993). It 
involves lots of subfamily like cytochrome P450 lAl，lA2, 3A4, etc., which 
participate in pathways of steroidogenesis from cholesterol, including steps leading 
to the synthesis of minerocorticoid, glucocorticoid, androgen and estrogen. It can 
also oxidize endogenous steroids, like testosterone, estrogen and their derivatives. 
It is widely believed that the estradiol-2-hydroxylase activity is mediated through 
the cytochrome P450 system (Jellinck et al., 1993). 
Cytochrome P450 lAl is usually expressed only after exposure to inducer, 
like environmentally ubiquitous chemical. The overall function of cytochrome 
P450 lAl may be explicable primarily only in conjunction with those of 
functionally related compounds (Denison and Whitlock Jr., 1995). Cytochrome 
^v 
P450 1A1 in mice and rats has been shown to be regulated at transcriptional level. 
The activation involves binding of the ligand, like tetrachlorodibenzo-dioxin 
(TCDD), 3-methylcholanthrene (3-MC) to aryl hydrocarbon receptor. It is then 
translocated to the nucleus and initiates the transcription in liver (Aoyama et al., 
1990). 
However, in uninduced cells, constitutively expressed general transcription 
factors fail to bind to cytochrome P450 1A1 promoter. On the other hand, 
cytochrome P450 1A2 is expressed primarily in the liver and the constitutive level 
of this enzyme is much greater than that of cytochrome P450 1A1 (Quattrochi et 
. al., 1994). 
The binding affinity of the ligand normally determines its potency as a 
cytochrome P450 1A1 inducer (Sutter et al., 1994). However, the difference in the 
着 
binding affinities between 3-MC and T C D D cannot account for their difference in 
activity, as they are metabolised at different rate (Riddick et aL, 1994). Aryl 
hydrocarbon receptor transformation efficacy may be a key determinant of 
maximum biological response produced by ligand in intact cell fRiddick et al., 
1994). 
^v 
To determine the role of cytochrome P450 isozyme in a particular reaction, 
cytochrome P450 chemical inhibitors are widely used. For example, to assess 
whether or not the 2- and 4-hydroxylation of estradiol are catalyzed by P450 
enzymes (Kerlan et al., 1992), microsomes were incubated with inhibitors, 
including caffeine, a specific inhibitor of cytochrome P450 lA2; troleandomycin 
and cimeditine for inhibiting cytochrome P450 3A4 etc. By inhibiting the specific 
subfamily ofcytochrome P450 isozymes and studying the changes in the particular 
enzyme activity, it can be concluded whether a specific cytochrome P450 isozyme 
play any role in the reaction. 
1.9 Yuehchukene 
Yuehchukene (YCK), a bis-mdolQ aUcaloid OFigure 1.10) isolated from the 
root of Murraya panicuIata, has been demonstrated to exhibit mixed estrogenic 
and anti-estrogenic activities Q^g et al., 1994). Yuehchukene was shown to bind to 
estrogen receptors, albeit at a fairly low relative binding affinity of 1/150 to 1/300 
with respect to estradiol. Yuehchukene could induce ornithine decarboxylase 
activity, another model for investigating estrogenicity, although the induction is 
weaker than estradiol. The results from the estrogenicity studies suggested that 
yuehchukene is not only a partial agonist with limited estrogenicity, but it may also 
inhibit the fiill expression ofestrogenic activity. The estrogenicity ofyuehchukene 
lies in the relative planarity ofthe two indole moieties. Enantio-selective synthesis 
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of camphor-yuehchukene enantiomers showed that only yuehchukene with a R(+)-
enantiomer was active in the rat anti-implantation assay OHo et al., 1991). Jn 
yuehchukene racemate, methyl, but not phenyl substitution, on C-2 of the free 
indole enhanced activity, whereas removal of the gem-dimethyl group rendered 
yuehchukene inactive (Cheng et al., 1992). These structural constraints in fact 
limited the stereochemistry of the ‘free，indole to lie below the indole plane and 
wedged between the gem-dimethyl group and the tetracyclic plane in an actue 
angle. Such a stringent geometrical requirement strongly suggested specific 
receptor binding in the expression of yuehchukene estrogenicity. Yuehchukene 
was originally developed out of an international collabrative research program 
sponsored by the World Health Organization in search of fertility regulation agents 
from plant source. It is found that the R (+) enantiomer is the active form. It was 
equipotent with (±)-yxiehchukene in both anti-implantation and estrogenic activity 
test (Ho et al., 1991). Methylbutadienyl-indole, the immediate biomimetic _ 
precursor of Y C K (Figure 1.10), also activates the estradiol-2-hydroxylase 
reaction, as well as cytochrome P450 1A1, measured as the ethoxyresorufm-0-
deethylase OEROD) activity. 
1.10 Objectives ofthe Present Study 
Jn the present study, structural isomers of indole-carbinols and 
methylbutadienyl-indoles, as well as the relevant derivatives were tested on their 
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induction effects on ethoxyresorufm-0-deethylase and estradiol-2-hydroxylase 
activity. Attempts were made to investigate whether the induction effects of the 
two enzyme activities were parallel with each other. Moreover, administration of 
isoprenyl compounds to aryl hydrocarbon receptor-knockout mice showed that the 
aryl hydrocarbon receptor is important in mediating the induction of both 
ethoxyresorufm-0-deethylase and estradiol-2-hydroxylase. 
^ 
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2. Materials and Methods 
2.1 Animals 
Six weeks old female Balb/c (body weight: 19-22 g) and C57B/6 (body weight: 
14-17 g) mice were obtained from the Animal House of the Chinese University of 
Hong Kong. The aryl hydrocarbon receptor-knockout mice (body weight: 15-17 g) are 
of mixed genetic background (Sv/129/ter x C57B/6) ^Femandez-Salguero et al.., 
1995). A pair of parental stocks of aryl hydrocarbon receptor-knockout mice was 
shipped from the National Cancer Institute (National Institutes of Health, Bethesda, 
M D , USA). They were then bred and reared at the Chinese University of Hong Kong 
animal rooms on a 12 h light/dark cycle (light: 06:00-18:00) period. They were used 
to determine whether the aryl hydrocarbon receptor was involved in the induction of 
ethoxyresorufin-0-deethylase and estradiol-2-hydroxylase activity. 
2.2 Animal Treatment 
After ovemight fasting, the mice were given a single dose of the test 
compounds through p.o. administration. The test compounds, including 2'-
methylbutadienyl-indole, 3'-methylbutadienyl-indole, isopropyl indolo-carbazole, 
yuehchukene, indole-2-carbinol, indole-3-carbinol, indole-2-carboxyaldehyde, indole-
3-carboxyaldehyde and 3-methylcholanthrene, were first dissolved in absolute ethanol 
before 19 volumes of olive oil were added. For the control group, the mice were given 
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5% ethanol in olive oil instead. After treatment, the mice were fasted for another 9 h; 
they were then given free access to food and water for 15 h before being sacrifice. 
2.3 Preparation of Crude Microsomal Fraction 
The mice were sacrificed by cervical dislocation. Their livers were excised. 
Livers from two mice were pooled together and treated as one sample. Each sample 
was immediately homogenized in ice-cold 1 m M EDTA, 1 m M dithiothreitol, 10% 
glycerol, 10 m M Hepes, pH 7.4 (1:4 w/v) using a Pyrex glass homogemzer. The 
homogenates were centrifuged at 1,200 g for 30 min at 4°C. The supernatant fractions 
were further centrifuged at 105,000 g for 1 h at 4°C. The pellets were resuspended in 
0.1 M potassium phosphate, pH 7.4 containing 1 m M EDTA, 1 m M dithiothreitol, 
20% glycerol. The preparations were stored at -70°C before use. 
2.4 Protein Assay 
The protein content was determined by the method of Bradford (1976), using 
bovine serum albumin as the standard. 
2.5 Ethoxyresorufin-0-deethylase Assay 
The assay was performed according to the procedure of Pohl and Fouts (1980). 
Twenty five ^ig of protein was incubated in 0.5 ml of an assay medium containing 0.1 
m M magnesium sulfate, 1.6 mg bovine serum albumin, 1.5 ^ M ethoxyresorufm, 50 
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m M potassium phosphate, pH 7.5. The reaction was initiated by the addition of 150 yd 
NADPH-regenerating system (0.2 unit of glucose-6-phosphate dehydrogenase, 0.28 
m M p-NADP and 2.5 m M glucose-6-phosphate). After incubation at 37。C for 15 min, 
the reaction was terminated by precipitating the protein with 1 ml methanol. After 
centrifugation, the supernatant fluid was taken for fluorescence measurement with an 
excitation wavelength of 530 nm and an emission wavelength of 590 mn. The 
fluorescence was measured by Cytoflour 2350. The amount of resorufin produced 
was determined with reference to the standard curve. 
2.6 Methoxyresorufln-0-deethylase Assay 
The procedure was similar to that used for studying ethoxyresorufm-0-
deethylase, with the exception that methoxyresorufin was used as the substrate instead 
of ethoxyresorufm. 
2.7 Estradiol-2:hydroxylase Assay 
Estradiol-2-hydroxylase activity was determined by following the formation of 
^ 2 0 from [2-^CN)] estradiol (15 Ci/mmol). Fifty \ig of protein was incubated in 1 
ml of 50 m M potassium phosphate, pH 7.4，containing 0.1 m M magnesium sulfate, 
1.6 m g bovine serum albumin and 40 n M [ 2 - ¾ ^ ] estradiol. The reaction was 
initiated by the addition of 150 i^l NADPH-regenerating system as described in 
Section 2.5. The mixture was incubated at 3TC for 10 min before the reaction was 
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stopped by 200 ^ il of30% trichloroacetic acid. One ml of dextran-charcoal suspension 
(0.05% dextran T-70 and 0.5% Norit-A) in 50 m M Tris-HCl, pH 7.4，was added to 
adsorb the unreacted [2-¾^^^] estradiol. At least 99.85% of the substrate was 
removed by such treatment. The mixture was allowed to stand at 4°C for 15 min 
before being centrifuged at 1,500 g for 15 min. Aliquots of0.5 ml were transferred to 
4 ml scintillant for radioactivity determination. The radioactivity was measured by 
Beckman LS 1801 liquid scintillantion counter. 
2.8 Progesterone Hydroxylase Assay 
The procedure was similar to that used for studying estradiol-2-hydroxylase, 
with the exception that [l,2-¾C^0] progesterone was used as the substrate instead of 
•‘ 
[2-^N)] estradiol. 
2.9 Hepatic Aromatase Activity Assay 
Fifty ^ ig hepatic microsomal protein was pre-incubated at 37°C in 900 i^l of 
6 7 m M potassium phosphate buffer, pH 7.5 containing 5mg B S A and 40 n M ip-^-
androsteinedione. After 2 min of incubation, the reaction was initiated by the addition 
of 5 m g N A D P H in 0.1 ml of phosphate buffer. The reaction was allowed to proceed 
for 10 min before terminated by adding 0.25 ml 20% T C A and 0.5 ml dextran-
charcoal suspension (0.05% Dextran T-70 and 0.5% Norit-A) in 50 m M Tris-HCl, pH 
7.4. The mixture was then incubated in a 37°C water bath for 30 min. After 
^v 
centrifuging at 3,000 rpm to pellet the charcoal suspension, 0.5 ml clear supernatant 
was taken and mixed with 5 ml scintillant. The radioactivity was measured by 
Beckman LS 1801 liquid scintillantion counter. 
2.10 Inhibition of Ethoxyresorufin-0-deethylase and Estradiol-2-
hydroxylase 
The assay was conducted according to the procedures described in Sections 2.5 
and 2.7. Compounds such as troleandomycin, cimetidine, cyproterone acetate, 
caffeine, a-naphthoflavone previously dissolved in 5p,l methanoV water were included 
in the reaction mixture. The concentration of the inhibitor used was based on the 
highest concentration used by Kerlan et aL,1992. Control experiments were 
conducted with the same amount of methanol or water. Moreover, different 
concentration of indole-3-carbinol, 3'-methylbutadienyl-indole and yuehchukene were 
added to the above medium, to see whether there is any in vitro effect on the enzyme 
activity. ‘ 
2.11 Free Radicals Scavenging Assay 
Lidole-3-carbinol, indole-2-carbinol and indole-3-carboxyaldehyde were 
dissolved in water. 3'-Methylbutadienyl-indole and yuehchukene were dissolved in 
41% and 20% ethanol respectively. The 2,2‘-azino-bis(3-ethylbenzthiazdine-6-
sulfonic acid)-radical (ABTS-radical) was prepared by adding 0.5 ^iM horseradish 
^v 
peroxidase to an assay medium of 50 m M glycine-HCl buffer, pH 4.5 containing 50 
^iM ABTS, 25 ^iM hydrogen peroxide. The medium was incubated for 5 min for 
ABTS radical formation and system equilibration. Then, different isoprenyl 
compounds were added to the medium and incubated for another 5 min. The reaction 
between ABTS radical and the isoprenyl compounds was measured by following the 
by the decrease in absorbance at 414 nm. 
2.12 Chemicals 
2 ‘ -Methylbutadienyl-indole, 3'-methylbutadienyl-indole, isopropyl indolo-
carbazole, yuehchukene, indole-2-carboxyaldehyde and indole-3-carboxyaldehyde 
were kindly provided by Dr. K.F. Cheng, Department of Chemistry, the University of 
Hong Kong. Lidole-2-carbinol and indole-3-carbinol were obtained from Aldrich. 
Hepes, EDTA, 3 -Methylcholanthrene, ethoxyresorufm, methoxyresorufm, resorufm, 
activated charcoal fNorit-A), dithiothreitol, potassium phosphate, magnesium sulfate, 
glucose-6-phosphate,^ P-NADP, NADPH, glucose-6-phosphate dehydrogenase, bovine 
serum albumin, trichloroacetic acid, Tween-20, troleandomycin, cimetidine, 
cyproterone acetate, caffeine, a-naphthoflavone, ABTS, horseradish peroxidase, 
glycine were all purchased from Sigma Chemical Co. The labeled substrate [2-¾^^)] 
estradiol (15 Ci/mmol), [lp-^-androsteinedione (23.1 Ci/mmol), [l,2-^qST)] 
progesterone (47.5 Ci/mmol) was from New England Nuclear. Dextran-T70 was 
^v 
purchased from Pharmacia. Hydrogen peroxide was from Merck. Methanol, ethanol, 
glycerol were purchased from British Drug House. 
^v 
3. Result 
3.1 Optimization of Condition 
3.1.1 Dosage 
To obtain the optimal conditions for the induction of the isoprenyl 
compounds on ethoxyresorufm-0-deethylase and estradiol-2-hydroxylase 
activities, Balb/c mice received different doses of indole-3-carbinol and 
3 'methylbutadienyl-indole through p.o. administration and were sacrificed after 
24 hours. Crude microsomal fraction was obtained to determine the enzyme 
... activities. Two different doses of the chemicals, 0.8 and 0.26 mmo^kg body 
weight were adopted. The results suggested that both enzyme induction showed 
dose-dependency and the dose of 0.8 mmol/kg body weight gave a more 
significant increase in both enzyme activities OFigures 3.1 and 3.2). As a result, 
0.8 mmol/kg body weight was chosen for the study of the effect of the different 
indole carbinols, carboxyaldehydes and isoprenyl compounds. 
3.1.2 Time for Sacrifice 
After the p.o. administration of the isoprenyl compounds, the mice were 
sacrificed at different time in order to investigate the time course for maximal 
induction. The time points chosen were 8, 24 and 48 h after the p.o. 
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Figure 3.1: Effect ofindole-3-carbinol and 3'-methylbutadienyl-indole on EROD activity. 
The mice were sacrificed 24 h after receiving the drug. 3-MC served as a positive control 
for ethoxyresonifin-0-deethylase induction, the assay was performed as described in 
Materials and Methods, (n=3) 
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Figure 3.2:Effect of indoie-3-carbinol and 3 '-methylbutadienyl-indole on estradiol-2-
hydroxylase. The mice were sacrificed 24 after receiving the dmg,. The assay was 
performed as stated in Materials and Methods (n=3). 
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administration. The results indicated that 24 h after op treatment of 
3'methylbutadienyl-indole gave the optimal induction in the activity of 
ethoxyresomfm-0-deethylase assay. For the indole-3-carbinol treated group, the 
induction of the ethoxyresorufm-0-deethylase activity continued to increase 
beyond 24 h (Figure 3.3). For the estradiol-2-hydroxylase activity, the effect was 
similar at both 24 ahd 48 h for both the indole-3-carbinol and 
3'methylbutadienyl-indole treated group OFigure 3.4). Consequently, 24 h after 
the P.O. administration was adopted as the time for sacrifice in further 
experiment. 
3.2 Effect of Isoprenyl Compounds on the Changes of Body 
Weight, Liver Weight and Hepatic Microsomal Protein Content 
Treatment with various isoprenyl compounds did not seem to trigger any 
significant changes on the body weight, liver weight and hepatic microsomal 
protein content (Table 3.1). The change ofbody weight differed by about 2 and 
8% after treating with the isoprenyl compounds and 3-MC respectively. The 
liver weight changed by less than 2 % after the treatment of the isoprenyl 
compounds. Similar situation was found in the total microsomal protein content 
in the treated and control groups with a change of less than 4%. To conclude 
from the above results, no distinct toxicity was observed after treating the mice 
with the different compounds. 
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Figure 3.3: Investigation of the time of sacrifice on the induction of ethoxyresomfin-0-
deethyase activity. After the administration of indole-3-carbinol and 3'-methylbutadienyl-
indole (0.8mmol/kg body weight), the mice were sacrificed at different time. 
Ethoxyresomfin-0-deethylase activity was assayed as described in Materials and Methods 
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Figure 3.4: Investigation of the time of sacrifice on the induction of e s t r a d i o l - 2 -
hydroxylase activity. After the administration of indole-3-carbinol and 3'-
methylbutadienyl-indole (0.8mmoL^kg body weight), the mice were sacrificed at different 
time. Estradiol-2-hydroxylase activity was assayed as described in Materials and Methods 
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Table 3.1: Effect of different isoprenyl compounds^ and 3-methylcholanthrene (3-MC) on 
body weight, liver weight and total microsomal protein content of Balb/c mice 
Treatment n Body weight (g) Liver weight (g) Total microsomal 
protein content 
(mg) 
Control 8 40.5 土2.98。 2.63±0.18 16.7±1.16 
Isoprenyl Compounds 22 39.6±2.19 2.59±0.21 16.1±2.22 
3-Methylcholanthrene 7 37.2±2.58d 2.45土0.20 16.6土1.99 
^ e isoprenyl compounds included indole-2-carbinol, indole-2-carboxyaldehyde, indole-
3-carbinol, indole-3-carboxyaldehyde, 2'-methylbutadienyl-indole, 3 '-methylbutadienyl-
indole, isopropyl indolocarbazole and yuehchukene. 
^n,Number of group of animal or tissue. The number in each group is two. 
CThe results were the mean of2 mice 土 S.D. 
S^tatistical significant difference (p<0.05) from corresponding control. Statistical analysis 
was done by using Student's t test. 
^ 
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3.3 Hepatic Enzyme Activities 
3.3.1 Ethoxyresoufin-O-deethylase 
The rationale of doing ethoxyresorufm-0-deethylase was to investigate 
whether there would be any induction after the p.o. administration of the 
chemicals. Jn all sets of experiments, 3-methylcholanthrene, the prototype 
inducer ofcytochrome P450 1A1 isozyme, was administered p.o. to the mice, so 
as to act as a positive control in the experiments. It was found that 3-
methylcholanthrene could induce the ethoxyresorufm-0-deethylase activity by 
more than 10 fold (Table 3.2). In the first set of experiment, the most potent 
indole compounds in inducing the ethoxyresorufm-0-deethylase was indole-2-
carbinol, which gave a 5.5 fold increase, whereas least induction was found in 
indole-2-carboxyaldehyde and displayed only a 2.6 fold increase, ]fedole-3-
carbinol and indole-3-carboxyaldehyde gave about 4.0 fold increase (Table 3.2， 
experiment set 1). 
Hi the case of methylbutadienyl-indoles, 2'- and 3'methylbutadienyl-
indole both gave significant induction, with the induction of 4 to 5 fold in the 
ethoxyresorufm-0-deethylase assay (Table 3.2，experiment set 2). 
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Table 3.2: Liduction of ethoxyresorufm-0-deetylase (EROD) activity, in Balb/c mice 
after the treatment of indole carbinols, their structural derivatives, methylbutadienyl-
indoles and their acid condensation products. 
Treatment Dose n^  EROD  
(mmoVkg body wt.) QjmoL^mWmg) 
(A) Experiment set 1 
Control 3 72.67 土 28.82 
I-2-C 0.8 3 393.00 ± 102.90b 
I-2-CA 0.8 3 1 8 5 . 7 7 ± 4 9 . 9 4 b 
I-3-C 0.8 3 296.81 ±69.83b 
I-3-CA 0.8 3 293.36±73.62b 
3-MC 1.0 2 783.32±117.83b 
(B) Experiment set 2 
Control 3 70.40±23.92 
2'-MBDI 0.8 3 287.00±36.6lb 
3'-MBDI 0.8 3 336.08 ±65.5lb 
3-MC 1.0 2^  959.05 il8.63 
(C) Experiment set 3 
Control 2 75.00±15.93 
n>P-ICZ 0.08 2^  391.67t72.32 
3-MC 1.0 2^  916.73i67.60 
(D) Experiment set 4 
Control 3 61.03 ±8.86 
Y C K 0.08 3 118.00±12.09b  
3-MC _L0 3 679.03 士 109.45b 
Female Balb/c mice were p.o. administered with the dose mentioned. They were 
sacrificed after 24 h. Hepatic microsome was prepared and EROD activities were 
assayed as described in the Materials and Methods. Results were expressed as mean 土 
S.D. — 
dumber of group of animals. Each group of sample contains two mice. 
Statistical significant difference Op<0.05) from corresponding control. Statistical analysis 
was performed by SigmaStat 2.0, Duncan multiple range test. 
S^tatistical analysis was not perfomed because of the limited number of sample. 
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Under the acidic conditions, 2 ‘ -methylbutadienyl-indole could condense 
to form isopropyl indolocarbazole OLee et al., 1996) and a similar reaction occurs 
for 3'-methylbutadienyl-indole to give yuehchukene. The yield of these acid 
condensation reactions were about 10%, hence, in studying their effects on the 
enzyme activities, a dose of only one-tenth were used for the studying the effect 
of these acid condensation products, i.e. 0.08 mmoVkg body weight was used in 
this set of experiment. The results showed that isopropyl indolocarbazole was 
more potent (5.2 fold) in inducing ethoxyresomfin-0-deethylase activity (Table 
3.2, experiment set 3) ； by contrast, yuehchukene showed an induction of only 
1.9 fold instead (Table 3.2, experiment set 4). 
The induction effect of indole-3-carbinol, 3 'methylbutadienyl-indole and 
3-methylcholanthrene was repeated using aryl hydrocarbon receptor-knockout 
mice, the animal model for comparison was C57/B6 mice. The C57/B6 mice 
一 
were the closest strain to the aryl hydrocarbon receptor-knockout mice. The 
induction pattem of the enzyme activity on C57/B6 mice, after the administration 
of isoprenyl compounds, was similar to that of the Balb/c mice. 3-
Methylcholanthrene showed the greatest induction, a 17.2 fold induction was 
found. For the mice treated with indole-3-carbinol and 3'methylbutadienyl-
indole, there were also significant inductions of 4.8 and 6.2 fold respectively. 
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Regarding the aryl hydrocarbon receptor-knockout mice, no significant 
induction in the enzyme activity was found, i.e. the 3’ substituted isoprenyl 
compounds, as well as 3-methylcholanthrene, could not induce any increase in 
the enzyme activity (Table 3.3). 
3.3.2 Methoxyresorufln-0-deethylase 
Cytochrome P450 1A2 is claimed to be the isozyme responsible for the 
induction of estradiol-2-hydroxylase (Shou et al., 1997)，thus methoxyresorufm-
0-deethylase, an enzyme assay which is specific for cytochrome P450 lA2, is 
also determined. All the isoprenyl compounds gave significant induction in the 
methoxyresourfin-0-deethylase assay. Similar to the ethoxyresorufin-0-
deethylase assay, indole-2-carbinol gave the greatest induction (5.5 fold) among 
all the carbinols and respective carboxyaldehydes tested. The least effective 
inducer was indoIe-2-carboxyaldehyde which showed only a 2.9 fold induction 
(Table 3.4，experiment set 1). 2‘-Methylbutadienyl-indole and its acid 
condensation product, isopropyl indolocarbazole both indicated the most 
effective induction, with an increase of 4.3 and 5.4 fold in activity respectively. 
On the other hand, the 3，- methylbutadienyl-indole also gave a significant 
induction of 3.8 fold (Table 3.4，experiment set 2), whereas yuehchukene 
exhibited a 1.9 fold induction. (Table 3.4, experiment set 3). 3-
Methylcholanthrene in these three experiment sets showed the greatest induction 
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Table 3.3: Comparison of the effect of induction of ethoxyresorufin-0-deethylase 
^EROD) activity, after the treatment of indole-3-carbinol, 3'-methylbutadienyl-indole (3'-
MBDQ and 3-methylcholanthrene (3-MC) in C57B/6 mice and aryl hydrocarbon 
receptor-knockout mice 
Treatment Dose i? EROD  
(mmoVkg body wt.) (pmoL^minAng) 
(A) C57B/6 mice 
Control 3 67.92 士 26.02 
I-3-C 0.8 3 324.80±81.93b 
3'-MBDI 0.8 3 418.73 i l 4 . 8 7 b 
3-MC 1.0 3 1171.53 ± 539.70b 
(B) Aryl hydrocarbon receptor-
knockout mice 
Control 3 15.51土3.39 
I-3-C 0.8 2 ' 6.75士6.15 
3'-MBDI 0.8 3 13.99土10.90  
3-MC y 3 . 14.82±4.80 
Female C57/B6 and aryl hydrocarbon-receptor knockout mice were p.o. administered 
with the dose mentioned. They were sacrificed after 24 h. Hepatic microsome was 
prepared and EROD activities were assayed as described in the Materials and Methods. 
Results were expressed as mean 士 S.D. 
d u m b e r of group of animals. Each group of sample contains two mice. 
^Statistical significant difference 0p<O.O5) from corresponding control. Statistical analysis 
was performed by SigmaStat 2.0, Ranks test 
^ 
^Statistical analysis was not performed because of the limited number of sample. 
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Table 3.4: Liduction of methoxyresorufm-0-deethylase (MROD) activity, in Balb/c mice 
after the treatment ofvarious isoprenyl compounds and 3-methylcholanthrene. 
Treatment Dose n^  M R O D  
(nunol/kg body wt) Qjmol/min/mg) 
(A) Experiment set 1 
Control 0.8 3 221.16土36.50 
I-2-C 0.8 3 1227.53 ±164.32^ 
I-2-CA 0.8 3 649.06 士 89.70b 
I-3-C 0.8 3 754.49il23.60b 
I-3-CA 0.8 3 1067.13 ±99.73b 
3-MC 1.0 2' 1449.33 土2.85 
(B) Experiment set 2 
Control 3 197.02±22.01 
2'-MBDI 0.8 3 845.51 ± 166.52b 
3'-MBDI 0.8 3 753.30 i213.25b 
EPP-ICZ 0.08 2' 1070.58±21.21 
3-MC 1.0 3 1131.81±35.22b 
(C) Experiment set 3 
Control 3 179.11±21.88 
Y C K 0.08 3 335.06 ±25.49b  
3-MC l_^  3 1641.20± 125.32b 
Female Balb/c mice were p.o. administered with the dose mentioned. They were 
sacrificed after 24 h. Hepatic microsome was prepared and M R O D activity was assayed 
as described in the Materials and Methods. The enzyme activities were expressed as 
mean 土 S.D. 
^ 
dumber of samples, each group of sample contains two mice. 
S^tatistical significant difference Q)<0.05) firom the corresponding control. Statistical 
analysis was performed by SigmaStat 2.0, Duncan multiple range test. 
S^tatistical analysis were not performed due to limited number of sample. 
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in the methoxyresomfm-0-deethylase assay. As a whole, similar induction 
trend, as that of ethoxyresorufm-0-deethylase, was found in the 
methoxyresomfm-0-deethylase assay. 
3.3.3 Estradiol-2-hydroxylase 
Estradiol-2-hydroxylase is a direct measure of the hydroxylation of 
estradiol on C-2 position. The enzyme assay is used to see which compound is 
potent in inducing estradiol-2-hydroxylase. Jn the experiment set 1, among all 
the carbinols and carboxyaldehydes tested, only indole-3-carbinol showed a 
significant induction of 2.0 fold. For the rest of the indole carbinols and 
carboxyaldehydes, none of them managed to induce significantly the estradiol-2-
hydroxylase activity (Table 3.5, experiment set 1). 
For the, experiment involving methylbutadienyl-indoles, 3'-
methylbutadienyl-indole showed the greatest induction, with also a nearly 2.0 
fold increase as compared with the control. For 2 ‘ -methylbutadienyl-indole, the 
increase in the enzyme activity was only 27% (Table 3.5, experiment set 2). 
For the acid condensation products of methylbutadienyl-indole, 
yuehchukene could effectively induce the estradiol-2-hydroxylase activity by 2.0 
fold (Table 3.5, experiment set 4)，whereas isopropyl indolocarbazole could 
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Table 3.5: Liduction of hepatic estradiol-2-hydroxylase activity after the treatment of 
indole carbinols, their corresponding structural derivatives, methylbutadienyl-indoles and 
their acid condensation products. 
Treatment Dose n^  E2-2-OHase  
(mmol/kg body wt.) Q)molAninAng) 
(A) Experiment set 1 
Control 3 1.40±0.19 
I-2-C 0.8 3 1.53 ±0.29 
I-2-CA 0.8 3 1.01±0.23 
I-3-C 0.8 3 2.79±0.50b 
I-3-CA 0.8 3 1.41±0.14 
3-MC 1.0 3 1.64±0.28 
(B) Experiment set 2 
Control 3 1.39士0.23 
2'-MBDI 0.8 3 1.76土0.18 
3'-MBDI 0.8 3 2.45 ±0.30b 
3-MC 1.0 2^  1.56土0.10 
(C) Experiment set 3 
Control 2 1.02±0.20 
n>P-ICZ 0.08 2^  1.45±0.25 
3-MC 1.0 2c 1.57±0.19 
(D) Experiment set 4 
Control 3 1.65±0.37 
Y C K 0.08 3 3 .10±0.6lb 
3-MC l_^  3 1.32±0.29 
Female Balb/c mice were p.o. administered with the dose mentioned. They were 
sacrificed after 24 h. Estradiol-2-hydroxylase was assayed, as described in Materials and 
Methods. Results of the estradiol-2-hydroxylase were expressed as mean 土 S.D. 
dumber of sample, each group of sample contains two mice. 
S^tatistical statistical significance (^ p<0.05) compared with the corresponding control. 
Statistical analysis was performed by SigmaStat 2.0, Duncan multiple range test 
S^tatistical analysis was not performed, due to the limited number of sample. 
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increase the enzyme activity by only 42% (Table 3.5, experiment set 3). The 
prototype inducer of cytochrome P450 1A1, 3-methylcholanthrene could only 
induce the hydroxylase activity by less than 50% in all the four sets of 
experiment. To conclude, only 3'-substituted compounds, except indole-3-
carboxyaldehyde, were capable in inducing estradiol-2-hydroxylase. 
Li the aryl hydrocarbon receptor-knockout mice, no estradiol-2-
hydroxylase was induced, no matter which isoprenyl compounds were 
administered to the mice. However, in the control group of C57/B6 mice, a 
similar induction fold as seen in Balb/c mice was found. Lidole-3-carbinol, 3' 
methylbutadienyl-indole as well as 3-methylcholanthrene could induce the 
estradiol-2-hydroxylase by about 2 fold (Table 3.6). 
3.3.4 Progesterone Hydroxylase 
The estradiol-2-hydroxylation was a conventional method for measuring • 
the hydroxylation on estradiol, specifically on the C-2 position. Jn order to 
examine whether the exchange is specific for labelled estradiol, progesterone 
with the hydrogen labelled at C-1 and C-2 positions were used. The results 
indicated that the treatment with indole carbinols, indole carboxyaldehydes, 
methylbutadienyl-indoles and the relevant acidic condensation products did not 
show any significant change in the progesterone hydroxylase activity (Table 3.7). 
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Table 3.6: Comparison of the effect of induction of hepatic estradiol-2-hydroxylase, after 
the treatment of indole-3-carbinol (I-3-C), 3"methylbutadienyl-indole (3'-MBDI) and 3-
methylcholanthrene (3-MC) in C57B/6 mice and aryl hydrocarbon receptor-knockout 
mice. 
Treatment Dose n^  E2-2-OHase  
(mmoVkg body wt.) • (pmoVminAng) 
(A) C57B/6 mice 
Control 3 0.76 土 0.33 
I-3-C 0.8 3 1.61士0.47 
3'-MBDI 0.8 3 1.46±0.10b 
3-MC 1.0 3 1.56±0.29b 
(B)Aryl hydrocarbon 
receptor-knockout mice 
Control 3 0.51±0.09 
I-3-C 0.8 2^  0.40±0.22 
3'-MBDI 0.8 3 0.69士0.58  
^ L0 3 0.63±0.26 
Female C57/B6 and aryl hydrocarbon receptor-knockout mice were p.o. administered 
with the dose mentioned. They were sacrificed after 24 h. Hepatic microsome was 
prepared and estradiol-2-hydroxyase activities were assayed as described in the Materials 
and Methods. Results were expressed as mean 土 S.D. 
dumber of sample, each group of sample contains two mice. 
Statistical significant difference Q)<0.05) from the corresponding control. Statistical 
analysis was performed by SigmaStat 2.0, Ranks test. 
^ 
*^ Statistical analysis was not performed due to the limited number of sample. 
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Table 3.7:Comparison of the effect of induction of estradiol-2-hydroxylase and 
progesterone hydroxylase in Balb/c mice. 
Treatment n^  Estradiol-2-hydroxylase Progesterone 
Q)mob'miny'mg) hydroxylase 
OpmolAninAng) 
Control 2 0.78 ±0.16 0.69±0.10 
I-2-C 2b 1.07土0.45 0.56±0.19 
I-2-CA 2^  1.05士0.24 0.57士0.01 
I-3-C 2b 2.03± 1.20 0.55 ±0.05 
I-3-CA t 1.21±0.75 0.72±0.33 
2'-MBDI 2b 1.26±0.48 0.58±0.12 
3'-MBDI t 1.74±0.28 0.58±0.24 
3 - M C ^ 0 . 9 8 ± 0 . 0 7 . 0 . 5 4 土 0 . 0 5 
Female Balb/c mice were op administered with the dose mentioned. They were sacrificed 
after 24 h. Hepatic microsome was prepared and estradiol-2-hydroxylase and 
progesterone hydroxylase activities were assayed as described in the Materials and 
Methods. Results were expressed as mean 土 S.D. 
dumber of group ofanimals. Each group of sample contains two mice. 




With treatment of indole carbinols and their respective carboxyaldehydes, 
the Balb/c mice failed to show any change in the aromatase activities. Li the 
treatment of the methylbutadienyl-indoles and their respective acid condensation 
products, there was also no significant change in the activity of aromatase (Table 
3.8). 
3.4 Effect of Inhibitors in Ethoxyresorufln-0-deethylase and 
Estradiol-2-Hydroxylase Assay 
Li the ethoxyresomfm-0-deethylase assay, the microsome from control 
animal group showed a greatest susceptibility to the inhibition of a-
naphthoflavone among the different kinds of inhibitors. a-Naphthoflavone could 
inhibit the enzyme activity by 90%. For the other inhibitors tested, the inhibition 
exhibited ranged was about 20%. 
For the microsome from indole-3-carbinol treated group, a-
naphthoflavone also gave the most effective inhibition, nearly all the 
ethoxyresorufm-0-deethylase activity was stopped by the inhibitor. On the other 
end was caffeine where the inhibition was less than 10%. The rest of the 
inhibitors could inhibit the enzyme activity were about 10%. For the 
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Table 3.8: Liduction of aromatase activity after the treatment of indole carbinols, indole 
carboxyaldehydes and isoprenyl compounds. 
Treatment Dose n^  Aromatase activity 
(mmoV kg body wt) (pmol/min/mg) 
Control 3 0.85 土 0.07 
I-2-C 0.8 3 0.71 ±0.06 
I-2-CA 0.8 3 0.91 ±0.17 
I-3-C 0.8 3 0.93 士0.04 
I-3-CA 0.8 3 0.85 土0.16 
2'-MBDI 0.8 3 0.87±0.20 
3'-MBDI 0.8 3 0.91 土0.15 
EPP-ICZ 0.08 2b 0.81±0.07 
Y C K 0.08 2b 0.83±0.01 
3-MC l_^  3 1.09±0.14 
Female Balb/c mice were p.o. administered with the dose mentioned. They were 
sacrificed after 24 h. Hepatic microsome was prepared and aromatase activities were 
assayed as described in the Materials and Methods. Results were expressed as mean 土 
S.D. 
dumber of sample, each contained liver pooled from two mice. 
S^tatistical analysis was not performed due to the limited number of sample. 
Statistical analysis was performed by SigmaStat 2.0，Duncan multiple range test 
^ 
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microsomes obtained firom 3 -methylbutadienyl-indole treated group, a-
napthoflavone was still the most powerful inhibitor in the ethoxyresorufm-0-
deethylase assay (Table 3.9). 
Lti the estradiol-2-hydroxylase assay, the inhibition was most obvious in 
a-naphthoflavone and cyproterone acetate, where a reduction of over 80% 
activity was observed. The rest of the inhibitors only gave a moderate reduction 
in activities of about 10-50%. For the microsome from indole-3-carbinol treated 
group, the enzyme activity was also inhibited in the presence of cimetidine, an 
obvious inhibition of 68% of enzyme activity was observed. Also a-
naphthoflavone and cyproterone acetate showed the greatest inhibition, as the 
activity was nearly completely halted. Similar trend was also observed in the 
microsome that was from the 3 'methylbutadienyl-indole treated group (Table 
3.10). . 
Hihibitions were also found as indole-3-carbinol, 3'-methylbutadienyl-
indole and yuehchukene were added to the assay medium in ethoxyresorufm-0-
deethylase (Table 3.11) and estradiol-2-hydroxylase (Table 3.12) 
68 
Table 3.9: Treatment of inhibitors to the control, I-3-C and 3'-MBDI microsome, in the 
ethoxyresomfin-0-deethylase (EROD) assay 
(A)Microsome from control EROD activity % inhibition 
mice (pmoyminy^mg)  
Solvent: water 
Control 70.80±17.2 0% 
Caffeine 63.32 ±9.44 10.6% 
Solvent: methanol 
Control 54.54 土 7.28 0% 
Cryproterone acetate 42.29 土 2.90 22.5% 
Troleandomycin 53.92 土 4.65 1.1% 
Cimeditine 42.96 土 11.26 21.2% 
a-naphthoflavone 5.96 ± 2.76 92.3% 
~(B) Microsome from I-3-C EROD activity % inhibition 
treated mice _olAninAng)  
Solvent: water 
Control 238.50 ± 18.66 0% 
Caffeine 221.70±8.91 7.0% 
Solvent: methanol 
Control 219.36土23.68 0% 
Cryproterone acetate 189.65 士 29.48 13.5% 
Troleandomycin 196.80土18.66 10.3% 
Cimeditine 192.00±6.22 12.5% 
a-naphthoflavone 9.15 土 1.48 95.8% 
(C) Microsome from 3'- EROD activity % inhibition 
MBDI treate4 mice (pmoL^min/mg)  
Solvent: water 
Control 296.81 土62.37 0% 
Caffeine 260.88 ± 58.09 12.1% 
Solvent: methanol 
Control 272.96 士 42.95 0% 
Cryproterone acetate 249.07± 93.90 8.8% 
Troleandomycin 249.25 土 29.95 8.7% 
Cimeditine 268.75 土 60.80 1.5% 
a-naphthoflavone 7.31 ±3.57 97.3% 
The EROD was assayed as the Materials and Methods described, except with the presence of 
inhibitors. The concentration of caffeine (dissolved in water), troleandomycin (dissolved in 
methanol) was 1000^iM, cyproterone acetate and cimeditine (dissolved in methanol) was 500^M 
and a-naphthoflavone was 20fiM (dissolved in methanol). The result was expressed as mean 土 
S.D. and average percentage of inhibition in the EROD activity. Activity was compared with 
respective control. 
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Table 3.10:Treatment of inhibitors to the control, I-3-C and 3'-MBDI microsome in the 
estradiol-2-hydroxylase 
(A)Microsome from control E2-2-OHase Q^ mol/miny^ mg) % inhibition  
mice  
Solvent: water ~ 
Control U6±0.47 0% 
Caffeine 1.03±0.43 11.6% 
Solvent: methanol 
Control 0.95 土 0.36 0% 
Cryproterone acetate 0.17士0.06 82.1% 
Troleandomycin 0.61 土 0.18 35.7% 
Cimedtine 0.49±0.01 48.4% 
a-naphthoflavone 0.07±0.03 92.1% 
(B) Microsome from I-3-C~~E2-2-OHase ^)moL/min/mg) % inhibition  
treated mice  
Solvent: water 
Control 2.31土0.08 0% 
Caffeine 2.30士0.02 0.21% 
Solvent: methanol 
Control 1.84±0.21 0% 
Cryproterone acetate 0.35 士 0.08 80.9% 
Troleandomycin 1.06 土 0.06 42.4% 
Cimeditine 0.59士0.13 67.9% 
a-naphthoflavone 0.17 土 0.02 91.0% 
~~(C) Microsome from 3'-~~E2-2-OHase (pmol/minAng) % inhibition 
MBDI treated mice  
Solvent: water 
Control (water) 2.95 士 0.30 0 % 
Caffeine 2.85±0.04 3.5% 
Solvent: methanol 
Control 2.25±0.01 0 % 
Cryproterone acetate 0.35 土 0.04 84.4% 
Troleandomycin 1.80 土 0.25 20.0% 
Cimeditine 1.05± 0.13 53.3% 
a-naphthoflavone 0.21 ±0.04 90.6% 
The estradiol-2-hydroxylase was assayed as the Materials and Methods described, except with 
the presence of inhibitors. The concentration of caffeine (dissolved in water), troleandomycin, 
(dissolved in methanol) was 1 0 0 0 _ , cryproterone acetate and cimeditine was 500^M 
(dissolved in methanol) and a-naphthoflavone was 20^M (dissolved in methanol). The result 
was expressed as mean 土 S.D. and average percentage of inhibition in the estradoiol-2-
hydroxylase activity. Activity was compared with respective control. 
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Table 3.11 Lavestigation of in vitro effect by adding I-3-C, 3'-MBDI and Y C K to the 
microsomes with different treatment to the EROD assay medium 
Microsome EROD Activity (pmob^minAng) — 
(A) Control microsome 70.80 土 17.20 
No treatment 4 2 . 3 9 土 0 . 8 8 
I-3-C 4.20±1.62 
3'-MBDI 40.03 i2.51 
YCK 
(B) Microsome from I-3-C treated mice 
No treatment 238.50±18.66 
I-3-C 165.25 土5.02 
(C) Microsome from 3'-MBDI treated mice 
No treatment 296.81±62.37 
3'-MBDI 2L64±2.15 
CD) Microsome from YCK treated mice 
No treatment 115 1 g 土 g yj  
X 2 ^ 75.02 土 8.30 
The EROD was assayed as the Materials and Methods described, except with the 
presence of I-3-C, 3'-MBDI and Y C K to the assay medium. The above chemicals were 
dissolved in methanol. The concentration of the chemical was 1000pM after adding to 
the assay medium. The result was expressed as mean 土 S.D. 
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Table 3.12 Livestigation of in vitro effect by adding I-3-C, 3'-MBDI and Y C K to the 
microsomes with different treatment to the estradiol-2-hydroxylase assay medium 
Microsome E2-2-OHase (pmoL^minAng)  
(A) Control microsome 1.16 土 0.47 
No treatment 0.61 土 0.26 
I-3-C 0.06 士 0.04 
3'-MBDI 0.62±0.02 
Y C K 
(B) Microsome from I-3-C treated mice 
No treatment 2.31 土 0.04 
I-3-C 0.81±0.12 
(C) Microsome from 3'-MBDI treated mice 
No treatment 2.95 土 0.30 
3'-MBDI 0.11土0.25 
(D) Microsome from YCK treated mice 
No treatment 2.83 土 021 
Y ^ 0.13±0.04  
The estradiol-2-hydroxylase was assayed as the Materials and Methods described, except 
with the presence of I-3-C, 3'-MBDI and Y C K to the assay medium. The above 
chemicals were dissolved in methanol. The concentration of the chemical was 1000^iM 
after adding to the assay medium. The result was expressed as mean 士 S.D. 
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3.5 Free Radical Scavenging Assay 
To test whether the compounds act as free radical scavenger, ABTS was 
used as the substrate for peroxidase. The addition of indole-3-carbinol to the 
medium showed the disappearance of the radical. The reaction was 
concentration-dependent. At a higher concentration of indole-3-carbinol, the 
ABTS radical disappeared faster. Ln the case of indole-3 -carboxaldehyde, it did 
not show any free radical scavenging ability OFigure 3.5). However, in the case of 
indole-2-carbinol, in the initial part after the addition of compound, it showed a 
disappearance of free radical, however, there was a rebound in absorption in 1 
minute after adding the compounds. It indicated that there was a re-appeareance 
of free radical after the free radical scavenging (Figure 3.6). 
bi the case of isoprenyl compounds, 3 'methylbutadienyl-indole and 
yuehchukene could not be dissolved in water, therefore, they were first dissolved 
in ethanol. The fmal concentration of ethanol in the assay for 
3 'methylbutadienyl-indole and yuehchukene was 41% and 20% respectively. 
The addition of ethanol did not lead to the removal of free radical. 
3 'Methylbutadienyl-indole showed a reduction in absorption, which was also 
concentration-dependent ^ i^gure 3.7). On the other hand, yuehchukene also 
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Figure 3.5 Reconstructed graph of effect of indole-3-carbinol in the free radical 
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decrease in absorbance at 414nm. The assay was described as in Materials and Methods. 
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Figure 3.6 Reconstructed graph of effect of indole-2-carbinol in the free radical 
scavenging assay. The reaction measure the removal of free radicals which results in a 
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4. Discussion 
Natural compounds have been tested for a long time in the chemoprevention 
of cancer. A current scientific view indicates that damages to numerous regulatory 
genes ultimately result in the development of invasive and metastatic cancer, 
which is the cuknination of the chronic disease process, carcinogenesis. The 
natural history of carcinogenesis and cancer provides a strong rationale for a 
preventive approach to the control of this disease and leads one to consider the 
possibility of active pharmacological intervention to arrest or reverse the process 
ofcarcinogenesis before invasion and metastasis occur. Such intervention is called 
chemoprevention. The clinical practice of chemoprevention is still in its infancy, 
although there is a wealth of data documenting its effectiveness in experimental 
animals. As genetic testing has the potential to identify a large number of people 
who are at increased risk for the development of invasive cancer, preventive 
strategies are becoming increasingly important (Hong and Spom, 1997). One of 
the most popular candidates for chemoprevention of breast cancer is indole-3-
carbinol. It is shown that after acidic condensation, indole-3-carbinol will be 
transformed into indolo[3,2(b)]carbazole. The indolo[3,2(b)]carbazole has been 
shown to possess both estrogenic and anti-estrogenic properties O^iu et al., 1994) 
and it is said to be the most potent aryl hydrocarbon receptor agonist OBjeldanes et 
al., 1991). 
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Treatment with indole-3-carbinol results in an induction of estradiol-2-
hydroxylase, which may account for the anti-estrogenic property of indole-3-
carbinol. After the administration of indole-3-carbinol in both animal model and 
cell culture, there is also an induction of cytochrome P450 1A1 activity CBjeldanes 
et al., 1991). As these two activities are subjected to the administration of indole-
3-carbinol, it is believed that cytochrome P450 1A1 is a strong candidate for 
estrogen hydroxylation. This is supported by the observation that after the 
administration of tetrachlorodibenzo-p-dioxin (TCDD) to MCF-7 human breast 
cancer cell line, there is an elevation of cytochrome P450 content and a marked 
increase in the microsomal hydroxylation of estradiol at the C-2, C-4, C-15 and C-
6 position of estradiol (Spink et al., 1991). Formation of the inactive 2-
hydroxylation metabolites at the expense of the formation of 16a-hydroxylated 
estrogens are beneficial to the women. The reduction of estrogenicity means the 
reduction of risk to<have breast cancer. 
The oxidative metabolism of estrogen molecules is predominant in the C-2 
to form 2-hydroxyestrogen, which is also referred to as 2-catecholestrogen. In 
most of the species studied, it is suggested that hydroxylation at the C-2 position 
proceeds to a larger extent than oxidative metabolism at other sites. For example, 
the ratio of 2- : 4- � 16a-hydroxylation of estrone in liver microsome of hamster 
was about 7: 4: 1 (Zhu et al., 1994). Li human, as much as 50% of estrogen is 
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hydroxylated at the C-2 position. For 16a-hydroxyestrone, it strongly promotes 
the cell growth in estrogen receptor positive MCF-7 breast cancer cell line fNebert， 
1993). Other studies concerning about the potencies of 2-hydroxyestrone and 16a-
hydroxyestrone in transforming cells study, suggested that 16a-hydroxyestrone 
caused an increase in unscheduled D N A synthesis, increased breast cancer cell 
growth, as compared with the 2-hydroxyestrone, which generally showed less 
activity than estradiol itself in inducing all breast cancer-related parameters 
(Swaneck and Fishman, 1988). 
Besides the study on C2 and C16a-hydroxylation of estradiol, the role ofC-
4 hydroxylation in the formation of breast cancer, is also under extensive 
investigation recently. The cloning of the inducible human cytochrome P450 
lBlcDNA has led to the hypothesis that the encoded enzyme catalysed estradiol-4-
• 
hydroxylation (Hayes et al., 1996). Li human and mouse uteri, rat pituitary and 
hamster kidney, the rate of estradiol-4-hydroxylation is very high. Furthermore, in 
the male hamster kidney, the carcinogenic and D N A damaging activity of 4 
hydroxyestradiol implicate that this metabolite is related to the estrogen-induced 
carcinogenesis. Considerable evidence exists from studies in the male Syrian 
hamster that 4-hydroxyestradiol is a potent estrogen and is tumorigenic (Li et al., 
1985). Moreover, there was a brief report by Liehr and Ricci (1996) showing that 
4-hydroxylation of estradiol is elevated in certain breast tumour model. Ln short, it 
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is pertinent to elucidate the contribution of 4-hydroxyestrone to the development of 
human cancer and to identify the enzymes that produce these metabolites. 
Xenoestrogens affect the rate and type of estradiol metabolites formed. 
Xenoestrogens may also bind directly with the estrogen receptor to modulate 
breast cell proliferation and thereby influence the development of breast cancer 
and other hormonally mediated diseases (Toniolo et al., 1995). 
Redox cycling between estrogens and their corresponding quinones yields 
reactive oxygen species that increase the rate of oxidative D N A base modifications 
(Malins, 1993). Lipid oxidation products may also function as endogenous D N A 
damaging agents (Ames et al., 1995). Ln addition, other types of reactions, such as 
methylation or phosphorylation, can affect key functional regions ofDNA like cell 
cycle genes critical for cell proliferation, development and growth. Exposure to 
xenohormones, like are antioxidants, hormone antagonists through diet, will either 
promote or impede the process of cell proliferation. 
It shows the impact of steroid hormones on interacting genetic and 
hormonal pathways critical for breast carcinogenesis. Naturally occuring or 
synthetic xenohormones may affect the process of tumorigenic transformation at 
both genotoxic (initiational) or epigenetic (post-initiational) levels. Central to the 
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bifunctional effect ofbioavailable estradiol is its enzymatic conversion to products 
with distinctive biological activity. The microsomal enzyme, aromatase, 17P_ 
oxidoreductase and steroid hydroxylases, cytochrome P450 1A1, lA2, 1B1 and 
2B2 are essential enzymes for steroid hormone metabolism OLiehr et al., 1995; 
Liehr and Ricci, 1996). The metabolites themselves or their oxidative products 
may directly induce genotoxic D N A damage and modulate the expression of 
oncogene, tumour suppressor gene，or cell cycle control gene. 
Additionally, hormones, their metabolites, and xenoestrogens may exert 
epigenetic, paracrine effects on preinitial cells via hormone and growth factor 
receptors or via intercellular gap junctional communication. These indirect effects 
predominantly operate during the post-initiational ^promotional) events of 
carcinogenic transformation. 
][n previous study, mixed estrogenic and anti-estrogenic activities exhibited 
by indole-3-carbinol have also been observed in yuehchukene, a 6/5-aUcaloid 
isolated from Murraya paniculata OR^ utaceae) (Ng et aL, 1994). The presence of 
the "mixed" activities have a particular potential in the treatment ofbreast cancer 
because it can modulate the level of estrogenic activity required for protecting 
against osteoporosis and heart disease. The study of the effects of 
isomers/structural derivatives of indole carbinols, methylbutadienyl-indoles and 
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their respective acid condensation products on ethoxyresorufm-0-deethylase and 
estradiol-2-hydroxylase is an attempt to understand the relationship between the 
cytochrome P450 lAl and estradiol-2-hydroxylation (Tiwari et al., 1994，Leighton 
et al., 1995，Spink et al., 1991). The results showed that only when the substituent 
is at C-3 position of the indole ring was the compound most effective in inducing 
the estradiol-2-hydroxylase activity. On the other hand, the carboxyaldehydes and 
the C-2 substituted compounds did not have any significant effects. However, they 
showed capability in inducing ethoxyresorufm-0-deethylase. The most obvious 
case to show the lack of correlation between these two activities were in the 3-
methylcholanthrene treated mice where a 10-fold induction was found in the 
ethoxyresorufm-0-deethylase; this contrasts dramatically with the less than 1 fold 
increase in estradiol-2-hydroxylase activity. 3-Methylcholanthrene is a well-
known inducer of cytochrome P450 lAl (Riddick et al., 1994) and the 
ethoxyresorufm-0-deethylase is also a standard assay for this isoform OPohl and 
Fouts, 1980). Thus the differential induction shown by 3-methylcholanthrene on 
the estradiol-2-hydroxylase and cytochrome P450 lAl activity suggested that any 
anti-estrogenlc enzyme activity was not carried out by cytochrome P450 lAl, or at 
least, this isoform was not the major enzyme system responsible for the expression 
of the estradiol-2-hydroxylase activity. 
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Lndole-3-carbinol as well as 3'-methylbutadienyl-indole were capable of 
inducing ethoxyresorufm-0-deethylase and estradiol-2-hydroxylase. However, the 
differences in the level of elevation between estradiol-2-hydroxylase activity and 
ethoxyresorufm-0-deethylase activity suggest that different P450s contribute to 
these activities. Yuehchukene seems to be the best compound among those tested 
in chemoprevention. Among different 3'-substituted compounds, only 
yuehchukene gave a relatively minor induction in ethoxyresorufm-0-deethylase, 
but a 2 fold induction in estradiol-2-hydroxylase. Since it is not desirable to have a 
high activity of cytochrome isozyme activity as cytochrome isozymes involve in 
biotransformation of xenobiotics into toxic substances. On the other hand, the 
increase in estradiol-2-hydroxylase activity contributes to the anti-carcinogenic 
activity in relation to estrogen-responsive tumours, by increasing the formation of 
catechol estrogens that are anti-estrogenic in cell culture OVIatucci and Fishman, 
1979). The development of yuehchukene can provide a new avenue to enhance the 
induction of estradiol-2-hydroxylase for chemoprevention purpose. 
It is reported that estradiol-2-hydroxylation is associated with cytochrome 
P450 lA isozyme (Tiwari et al., 1994). However, by plotting the estradiol-2-
hydroxylase activity against ethoxyresorufm-0-deethylase activity of the 
microsomes obtained from mice after the treatment with indole carbinols, 
methylbutadienyl-indoles or their acidic condensation products, it was found that 
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the points were scattered on the graph (Figure 4.1). The 3'-substituted 
compounds, except indole-3-carboxyaldehyde, shown to be the chemicals which 
are much potent in inducing estradiol-2-hydroxylase, as all of these points are 
situated higher than the other points. All the 3-methylcholanthrene points lie far 
right from the estradiol-2-hydroxylase axis, showed that they are the least potent in 
inducing estradiol-2-hydroxylase. 
All derivatives/ structural isomers of the indole carbinols and yuehchukene 
and all isoprenyl compounds were capable of inducing the ethoxyresorufm-0-
deethylase activity. However, for estradiol-2-hydroxylase, only C-3 substituted 
isoprenyl compounds could induce the activity by about 2 fold. This can be 
explained by the "cross-talk" hypothesis ^Charat and Saatcioglu, 1996). 
Compound, with structure similar to tetrachlorodibenzo-p-dioxin, like the 
isoprenyl compounds in the present study, can be involved in modulating the 
signal transduction pathway of estrogens and aryl hydrocarbon receptor ligands. 
Like tetrachlorodibenzo-p-dioxin, the basis of the anti-estrogenic action 
may be accounted for by different mechanisms. The aryl hydrocarbon receptor-
isoprenyl compound complex might interfere with the ability of the liganded 
estrogen receptor to activate transcription. Several lines of evidence support this 
suggestion. The most significant of these are, first, in the presence of isoprenyl 
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with 3-methylcholanthrene. 
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compounds and estradiol, estrogen receptor-dependent activation of cathepsin D 
m R N A accumulation is abrogated ^ KJiarat and Saatcioglu, 1996). Second, in the 
presence of aryl hydrocarbon receptor, the isoprenyl compounds inhibit estrogen 
receptor-mediated ligand-dependent transcriptional activation of a reporter 
construct in a transient transfection assay and it was found that the estrogen 
receptor and aryl hydrocarbon receptor were mutually inhibiting each other's 
transactivation potential depending on the availability of the ligand ^ Qiarat and 
Saatcioglu, 1996). For example, estradiol-estrogen receptor complex interferes 
with aryl hydrocarbon receptor transactivation potential. Then influx of isoprenyl 
compounds will cause the binding to aryl hydrocarbon receptor. Lidole-2-carbinol 
has a strong affmity to the receptor, and therefore account for a higher induction of 
ethoxyresorufm-0-deethylase activity. However, aryl hydrocarbon receptor 
inhibits the complex to bind to the estrogen receptor element that activate the 
estradiol-2-hydroxylase transcription and in tum reduce the activity of estradiol-2-
hydroxylase. However, in the case of the C-3 substituted isoprenyl compounds, 
the binding affinity to the aryl hydrocarbon receptor is not so high OBjeldanes et 
al.,1991) as compared with indole-2-carbinol. Therefore, the mutual inhibition 
will not be so strong. Therefore, this allows a higher estradiol-2-hydroxylase 
activity. Besides the mutual inhibition of the two receptors, the indirect 
communication also involved the bridging factor. Compounds with different 
structures or functional group will trigger the bridging factors with different 
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efficiency, so affect the binding affmity to the receptor and in tum influence the 
ethoxyresorufm-0-deethylase and estradiol-2-hydroxylase activities (Kharat and 
Saatcioglu, 1996). 
The induction of estradiol-2-hydroxylase requires the binding of the 
complex consisting of aryl hydrocarbon receptor and the isoprenyl compounds. 
The binding of the complex to estrogen response element leads to the induction of 
transcription estrogen hydroxylase and alternately increases the activity of the 
enzyme. This illustrates the importance of the presence of aryl hydrocarbon 
receptor in the induction of the ethoxyresorufm-0-deethylase and estradiol-2-
hydroxylase. Ln fact, aryl hydrocarbon receptor takes part as the mediator in the 
induction of the two enzyme activities. Since the unbound cytosolic aryl 
hydrocarbon receptor is assoicated with the heat shock protein, upon binding to the 
compounds, the 9S (270 to 300 kDa) cytosolic aryl hydrocarbon receptor complex 
acts as a ligand-induced transcription factor that interact with xenobiotic response 
element. This results in the transactivation of cytochrome P450 1A1 gene O^u et 
al., 1996). Therefore, as no induction was found in ethoxyresorufin-0-deethylase 
and estradiol-2-hydroxylase in the aryl hydrocarbon receptor-knockout mice, it is 
obvious that both activities were mediated through aryl hydrocarbon receptor. 
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In testing the specificity of estradiol in estradiol-2-hydroxylation, 
radioactive progesterone was used as substrate. The position of the tritium was at 
both the C-1 and C-2 position in progesterone. The results indicated that there 
were no increase in the activities between the control microsome and the 
microsome prepared from the treated mice. This implied that the specificity of 
estradiol-2-hydroxylation assay was high. 
Besides cytochrome P450 1A1, there were also studies reporting that 
estradiol-2-hydroxylation was associated with cytochrome P450 1A2 (Shou et al., 
1997). In fact, at least six cytochrome P450, lA2, 2B6, 3A4, 3A5, 2C9 and 4B1 
were involved in the formation of catechol estradiols in human and cytochrome 
P450 1A2 has the highest activity in the formation of 2-hydroxyestradiol and 2-
hydroxyestrone (Shou et al., 1997). Furthermore, cytochrome P450 1A2 was said 
to be the most actiye isozyme and aknost exclusively as estradiol-2-hydroxylase. 
However, in our study, 3-methylcholanthrene, the most potent inducer for 
methoxyresorufm-0-deethylase, was not in estradiol-2-hydroxylase induction. 
The induction fold for methoxyresorufm-0-deethylase was very similar to the one 
in ethoxyresorufm-0-deethylase. Therefore, cytochrome P450 1A2 may not be the 
major form responsible for estradiol-2-hydroxylation. The activitiy of 
methoxyresorufm-0-deethylase is always higher than that of ethoxyresorufm-0-
deethylase, suggesting that there may be an induction of the constitutive enzyme, 
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upon administration of isoprenyl compounds or the amount of the inducible form, 
is always lower than that of the constitutive form fNebert and Gonzalez, 1987; 
Chaloupka et al., 1994). 
hi fact, members of cytochrome P450 inducer, like 3-methylcholanthrene 
are recognised substrate for activation, suggesting that one major function of 
cytochrome P450 1A1 and 1A2 is to protect the organism against the potentially 
deleterious effects of such environmental ubiquitous chemicals. It is observed that 
cytochrome P450 1A1 is usually expressed only after exposure to the inducer 
(Jachau et al.，1990). It has a very broad tissue and species distribution. Thus, it 
would seem advantageous to the organism if cytochrome P450 1A1 isoform were 
expressed primarily in response to exposure to these kinds of chemicals. It will 
lead to rapid elimination andy'or activation of these chemicals (Jachau et aL, 1990). 
4» 
Cytochrome P450 1A2 isozyme has been of clinical interest because of the 
large number of drug interactions associated with induction and inhibition of the 
substrate, like theophylline. Theophylline metabolism is now known to be 
partially mediated by this enzyme (Campbell et al” 1987). Cytochrome P450 1A2 
activity varies widely between individual. Genetic polymorphism, environmental 
factors including cigarette smoking, charbroiled meat, cruciferous vegetables and a 
number of drugs produce increases in cytochrome P450 1A2 activity (Slaughter 
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and Edwards, 1995). Moreover, cytochrome P450 1A2 is confined to hepatic 
tissue and is expressed constitutively. It attacks certain endogenous substrate quite 
efficiently, for example, the aromatic hydroxylation ofestrogen. 
In order to fmd out which isoform is responsible for the induction of 
estradiol-2-hydroxylase activity, inhibitors specific for different isoforms were 
used. For instance, a-naphthoflavone is known to specifically inhibit cytochrome 
P450 1A1/1A2 OVturray and Reidy, 1990); troleandomycin and cimetidine have 
been shown to inhibit cytochrome P450 3A4 (Brian et aL, 1990; Galbraith and 
Michnovicz, 1989) selectively etc. The maximum percentage of inhibition is 40% 
for caffeine and cyproterone acetate, and 90% for cimetidine and troleandomycin 
(Kerlan et aL, 1992). The aim of using inhibitors in our study is to investigate 
which cytochrome P450 isoform is involved in catalyzing estradiol-2-hydroxylase 
reaction. The result indicated that in the control microsome, there is a significant 
inhibition in ethoxyresorufm-0-deethylase in the presence of a-naphthoflavone. 
This is expected as a-naphthoflavone inhibits cytochrome P450 lA and 
ethoxyresorufm-0-deethylase is the standard assay for cytochrome P450 lA. ti 
terms ofother inhibitors for inhibiting cytochrome P450 lA or 3A4, the inhibition 
was about 20%. Also, 3'-methylbutadienyl-indole would inhibit ethoxyresorufm-
0-deethylase. For the result in indole-3-carbinol and 3'-methylbutadienyl-indole 
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treated microsome, similar inhibition patterns were found, as in the control 
microsome. 
Lti terms of estradiol-2-hydroxylase, in the control microsome, the inhibitor 
which showed the greatest inhibition is a-naphthoflavone, cyproterone acetate and 
3'-methylbutadienyl-indole. This demonstrated that cytochrome P450 lA is 
important in the estradiol-2-hydroxylase activity. Cimetidine as well as 
troleandomycin, also caused a reduction in estradiol-2-hydroxylation activity, but 
to a different extent. Li the case of indole-3-carbinol treated microsome, the result 
showed an obvious reduction in estradiol-2-hydroxylase, in the presence of 
cimetidine. It suggested that cytochrome P450 3A4 isozyme is also important for 
estradiol-2-hydroxylation. Moreover, a-naphthoflavone and cyproterone acetate 
showed severe reduction in estradiol-2-hydroxylation in control, indole-3-carbinol 
and 3'-methylbutadienyl-indole microsome. To conclude from the above data, 
cytochrome P450 lA and 3A were involved in estradiol-2-hydroxylation, in both 
control and indole-3-carbinol treated microsome. The inhibition pattem in the 3'-
methylbutadienyl-indole treated microsome also followed a similar trend as the 
indole-3-carbinol treated microsome. 
Cytochrome P450 3A isoforms have a heavy involvement in the 
biotransformation of steroid hormones. Research on substrate specificity has been 
‘ 、 
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comparatively slow because the catalytic activity ofcytochrome P450 3A isoforms 
loss quickly during purification. Nevertheless, it seems clear that members of the 
cytochrome P450 3A subfamily as a whole are capable of catalyzing the 
monooxygenation ofawide variety ofsteroids. For people with a low cytochrome 
P450 3 A activity, there were a 5.4 fold increase in the incidence of aggressive 
bladder cancer, suggesting a role of cytochrome P450 3A in this disease CFleming 
etal.，1994). 
Hepatic aromatase was assayed so as to investigate whether the isoprenyl 
compounds could function as an aromatase inhibitor or inducer. Aromatase 
inhibits the conversion of androstenedione to estrone, thus, its inhibition will 
reduce the estrogenicity in the body. Therefore, none of the test compounds will 
function as aromatase inhibitor. 
To examine the ability of indole-3-carbinol and other isoprenyl indoles to 
scavenge free radical, the enzyme system consisting peroxidase, hydrogen 
peroxide and ABTS was used. ABTS is a peroxidase substrate which, when 
oxidized in the presence of hydrogen peroxide in a typical peroxidation reaction, 
generates a metastable radical with a characteristic absorption spectrum with a 
maximum at 414nm. The reaction product, a metastable radical, is very stable. It 
has a high molar extinction coefficient and is generated directly from its precursor. 
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It was shown that the addition of mdole-3-carbinol to a medium containing ABTS 
radical led to the disappearance of the radical. The reaction is concentration-
dependent. For methylbutadienyl-indole and yuehchukene, they both showed the 
free radical scarvenging property and the effect was time- and concentration-
dependent. However, it showed a rebound of absorption in the case of indole-2-
carbinol, that meant free radical re-appear in the reaction system. This implies that 
indole-2-carbinol cannot capture the free radicals effectively, and the free radicals 
escaped easily, especially when the concentration ofindole-2-carbinol was low. Jn 
the case of indole-2-carboxyaldehyde, no free radical scavenging property was 
observed. Therefore, the in vitro model proposed might explain why dietary 
indole-3-carbinol, methylbutadienyl-indole and yuehchukene may act as natural 
antioxidant and partially protect against free radical mediated chemical toxicity 
(Amao et al., 1996). The property of free radical scavenging exhibited by the 
isoprenyl compounds had particular advantages, as one of the factors for 
promoting breast cancer is the formation of free radical. Therefore, the ability to 
scavenge free radical helps to reduce the risk ofbreast cancer ODavis et al., 1997b). 
To sum up, the cytochrome P450 1A1 was not the main form of isozyme 
responsible for the induction of estradiol-2-hydroxylase. Based on the inhibitor 
study, cytochrome P450 3A4 would be one ofthe candidates for catalyzing such 
reaction. Moreover, aryl hydrocarbon receptor is important in mediating the 
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induction of ethoxyresorufm-0-deethylase and estradiol-2-hydroxylase. Also, 3'-
methylbutadienyl-indole and yuehchukene would possess free radical scavenging 




From the above studies, it has been suggested that cytochrome P450 1A1 is 
not the major enzyme system responsible for the induction of estradiol-2-
hydroxylation. Cytochrome P450 3A4 maybe one of a possible candidates for the 
estradiol hydroxylation. Regarding the induction of estradiol-2-hydroxylase and 
cytochrome P450 1A1 isozyme, aryl hydrocarbon is important the induction for 
the above two enzymes. Also the position of the functional groups will have an 
effect on the estradiol-2-hydroxylation, as the 2 fold induction can only be seen in 
the 3'-substituted chemicals. 
The simple structure of indole-3-carbinol limits the number and position of 
functional groups that can be added to give more potent derivatives for the 
induction of estradiol-2-hydroxylase. Li contrast, 3'-methylbutadienyl-indole 
may easily form derivatives due to its complex structure and these derivatives may 
have a greater potential in inducing estradiol-2-hydroxylase activity. 
Duax and Griffm (1987) determined the X ray crystal structures of both 
stereoisomers of tamoxifen and compared them with 17p-estradiol. Under the 
assumption that tamoxifen is converted to the 4-hydroxy derivative, an orientation 
of the molecule is postulated in which the hydroxylated phenyl group mimics the 
A ring of estradiol. The aromatic ring with the basic side chain extends nearly 
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perpendicular to the steroid skeleton and might cause conformation changes in the 
receptor molecules that give rise to anatagonistic activities. Therefore, by 
attaching different side chains to different ring structures, different degree of 
induction of estradiol-2-hydroxylation could be achieved. 
Ruenitz et al (1982) demonstrated that the introduction of hydroxy groups 
to the meta- or para-position of the P-phenyl ring reduced the binding affinities 
towards estrogen receptor by more than one order of magnitude and overcame the 
favourable effect of the hydroxy function in the a-phenyl group. However, the 
prerequisite is to bind to the estrogen receptor without mediating the estrogenic 
action. 
Besides modifying 3'-methylbutadienyl-indole, yuehchukene can also be 
the candidate for the structural modification. As yuehchukene is a dimeric form of _ 
3 ‘ -methylbutadienyl-indole, so more attachment points for functional group and 
aDcyl chain were allowed. 
Actually the major aim of all of these studies is the development of anti-
estrogens for the treatment of estrogen-related disorder such as malignant tumour 
of breast. The endocrine profile of these compounds is mainly determined by the 
positions of hydroxy functions that are capable of forming hydrogen bridges with 
the receptor protein and the shape of the lipophilic area around the centre of the 
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molecule. Both factors together can change the estrogenic potency of a given 
structure without affecting receptor binding. A consistent reduction of estrogenic 
response characterized the partial antagonist. The importance of an amino 
function for anti-estrogenic activity has akeady been pointed out in tamoxifen and 
the introduction of functional groups to the side chain of the compound has to be 
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